

KERYX BIOPHARMACEUTICALS INC
Form DEF 14A
October 10, 2014
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF
THE SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to Section 240.14a-12

KERYX BIOPHARMACEUTICALS, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x No fee required.

.. Fee computed on the table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form DEF 14A

- .. Fee paid previously with preliminary materials.

- .. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

Table of Contents

KERYX BIOPHARMACEUTICALS, INC.

750 Lexington Avenue

New York, New York 10022

Dear Stockholder:

You are cordially invited to our special meeting of stockholders, to be held at 10:00 a.m. local time, on Monday, November 17, 2014, at the offices of our legal counsel, Alston & Bird LLP, located at 90 Park Avenue, New York, New York 10016. At the meeting, the stockholders will be asked to approve an amendment to our 2013 Incentive Plan to increase the number of authorized shares issuable thereunder from 3,500,000 to 9,500,000. You will also have the opportunity to ask questions and make comments at the meeting.

It is important that your stock be represented at the meeting regardless of the number of shares you hold. You are encouraged to specify your voting preferences by marking our proxy card and returning it as directed. If you do attend the meeting and wish to vote in person, you may revoke your proxy at the meeting.

If you have any questions about the proxy statement, please contact Brian Adams, our General Counsel and Corporate Secretary, at (617) 466-3452.

We look forward to seeing you at the special meeting.

Sincerely,

Ron Bentsur
Chief Executive Officer

October 10, 2014

New York, New York

Table of Contents

KERYX BIOPHARMACEUTICALS, INC.

750 Lexington Avenue

New York, New York 10022

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS

The special meeting of stockholders of Keryx Biopharmaceuticals, Inc. will be held at the offices of our legal counsel, Alston & Bird LLP, located at 90 Park Avenue, New York, New York 10016, on Monday, November 17, 2014, at 10:00 a.m., local time. At the meeting, stockholders will consider and act on the following item:

The approval of an amendment to our 2013 Incentive Plan to increase the number of authorized shares issuable thereunder from 3,500,000 to 9,500,000.

Only those stockholders of record as of the close of business on October 6, 2014, are entitled to vote at the special meeting or any postponements or adjournments thereof. A complete list of stockholders entitled to vote at the special meeting will be available for your inspection beginning October 9, 2014, at our offices located at 750 Lexington Avenue, New York, New York 10022, between the hours of 10:00 a.m. and 5:00 p.m., local time, each business day.

YOUR VOTE IS IMPORTANT!

You may vote your shares by completing and returning the enclosed proxy card.

Submitting your proxy does not affect your right to vote in person if you decide to attend the special meeting. You are urged to submit your proxy as soon as possible, regardless of whether or not you expect to attend the special meeting. You may revoke your proxy at any time before it is exercised at the special meeting by (i) delivering written notice to our General Counsel and Corporate Secretary, Brian Adams, at our address above, (ii) submitting a later dated proxy card or (iii) attending the special meeting and voting in person. No revocation under (i) or (ii) will be effective unless written notice or the proxy card is received by our General Counsel at or before the special meeting.

When you submit your proxy, you authorize Ron Bentsur, James F. Oliviero and Brian Adams to vote your shares at the special meeting and on any adjournments of the special meeting in accordance with your instructions.

By Order of the Board of Directors,

Brian Adams
Corporate Secretary

October 10, 2014

New York, New York

Table of Contents

KERYX BIOPHARMACEUTICALS, INC.

750 Lexington Avenue

New York, New York 10022

Phone: (212) 531-5965

Fax: (212) 531-5961

PROXY STATEMENT

This proxy statement and the accompanying proxy card are being mailed, beginning on or about October 10, 2014, to the owners of our shares of common stock as of October 6, 2014, in connection with the solicitation of proxies by our Board of Directors for our special meeting of stockholders.

The special meeting will take place at the offices of our legal counsel, Alston & Bird LLP, located at 90 Park Avenue, New York, New York 10016 on Monday, November 17, 2014, at 10:00 a.m., local time. Our Board of Directors encourages you to read this document thoroughly and take this opportunity to vote, via proxy, on the matters to be decided at the special meeting. As discussed below, you may revoke your proxy at any time before your shares are voted at the special meeting.

Table of Contents

Table of Contents

<u>QUESTIONS AND ANSWERS</u>	1
<i><u>Q. What is the purpose of the special meeting?</u></i>	1
<i><u>Q. Who is entitled to vote at our special meeting?</u></i>	1
<i><u>Q. How do I vote?</u></i>	1
<i><u>Q. What is a proxy?</u></i>	1
<i><u>Q. How will my shares be voted if I vote by proxy?</u></i>	1
<i><u>Q. How do I revoke my proxy?</u></i>	1
<i><u>Q. Is my vote confidential?</u></i>	2
<i><u>Q. How are votes counted?</u></i>	2
<i><u>Q. What constitutes a quorum at the special meeting?</u></i>	2
<i><u>Q. What vote is required to approve an amendment to our 2013 Incentive Plan to increase the number of authorized shares issuable thereunder from 3,500,000 to 9,500,000?</u></i>	2
<i><u>Q. What percentage of our outstanding common stock do our directors and executive officers own?</u></i>	2
<i><u>Q. How can I obtain a copy of our annual report on Form 10-K?</u></i>	3
<i><u>Compensation Philosophy and Objectives</u></i>	4
<i><u>Determining Executive Compensation</u></i>	4
<i><u>Elements of Compensation</u></i>	5
<i><u>Consideration of Last Year's Advisory Stockholder Vote on Executive Compensation</u></i>	5
<i><u>2013 Executive Compensation</u></i>	6
<i><u>Perquisites and Other Executive Benefits</u></i>	8
<i><u>Severance Benefits</u></i>	8
<i><u>2014 Executive Compensation</u></i>	9
<i><u>Report of the Compensation Committee</u></i>	9
<u>RISK ASSESSMENT OF COMPENSATION PROGRAMS</u>	10
<u>EXECUTIVE COMPENSATION</u>	11
<i><u>Summary Compensation Table</u></i>	11
<i><u>Grants of Plan-Based Awards For Fiscal Year 2013</u></i>	11
<i><u>Outstanding Equity Awards at 2013 Fiscal Year End</u></i>	13
<i><u>Option Exercises and Stock Vested in Fiscal Year 2013</u></i>	15
<i><u>Potential Payments upon Termination or Change in Control</u></i>	15
<u>DIRECTOR COMPENSATION</u>	19
<i><u>2013 Director Compensation</u></i>	19
<u>COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION</u>	21
<u>STOCK OWNERSHIP OF OUR DIRECTORS, EXECUTIVE OFFICERS, AND 5% BENEFICIAL OWNERS</u>	22
<u>PROPOSAL ONE:</u>	24
<u>APPROVAL OF AMENDMENT OF OUR 2013 INCENTIVE PLAN</u>	24
<u>ADDITIONAL INFORMATION</u>	35
<i><u>Householding of Special Meeting Materials</u></i>	35
<i><u>Other Matters</u></i>	35

Solicitation of Proxies

Amendment to the Keryx Biopharmaceuticals, Inc. 2013 Incentive Plan

Keryx Biopharmaceuticals, Inc., 2013 Incentive Plan

35

Exhibit A

Exhibit B

Table of Contents

QUESTIONS AND ANSWERS

Q. What is the purpose of the special meeting?

- A. At the special meeting, our stockholders will act upon the matter outlined in the notice of special meeting of stockholders accompanying this proxy statement, which is the approval of an amendment to our 2013 Incentive Plan to increase the number of authorized shares issuable thereunder from 3,500,000 to 9,500,000.

Q. Who is entitled to vote at our special meeting?

- A. The record holders of our common stock at the close of business on the record date, October 6, 2014, may vote at the special meeting. Each share of our common stock is entitled to one vote. There were 91,964,423 shares of common stock outstanding on the record date and entitled to vote at the special meeting. A list of stockholders entitled to vote at the special meeting, including the address of and number of shares held by each stockholder of record, will be available for your inspection beginning October 9, 2014, at our offices located at 750 Lexington Avenue, New York, New York 10022, between the hours of 10:00 a.m. and 5:00 p.m., local time, each business day.

Q. How do I vote?

- A. You may vote in person at the Special Meeting or by completing and returning the enclosed proxy card. To vote, simply mark, sign and date the enclosed proxy card, and return it in the enclosed postage-paid envelope. Alternatively, you may deliver your proxy card to us in person, by facsimile at (212) 531-5961 or by a courier to our offices at the address above. If you hold your shares through a broker, bank, or other nominee, you will receive separate instructions from the broker, bank, or nominee describing how to vote your shares.

Q. What is a proxy?

- A. A proxy is a person you appoint to vote your shares of our common stock on your behalf. If you are unable to attend the special meeting, our Board of Directors is seeking your appointment of a proxy so that your shares of our common stock may be voted. If you vote by proxy, you will be designating Ron Bentsur, our Chief Executive Officer, James F. Oliviero, our Chief Financial Officer and Treasurer and Brian Adam, our General Counsel and Corporate Secretary, as your proxies. Mr. Bentsur, Mr. Oliviero and/or Mr. Adams may act on your behalf and have the authority to appoint a substitute to act as your proxy.

Q. How will my shares be voted if I vote by proxy?

- A. Your proxy will be voted according to the instructions you provide. **If you complete and submit your proxy but do not otherwise provide instructions on how to vote your shares, your shares will be voted FOR the approval of an amendment to our 2013 Incentive Plan to increase the number of authorized shares issuable thereunder from 3,500,000 to 9,500,000.** Presently, our Board of Directors does not know of any other matter that may come before the special meeting. However, your proxies are authorized to vote on your behalf, using their discretion, on any other business that properly comes before the special meeting.

Q. *How do I revoke my proxy?*

- A. You may revoke your proxy at any time before your shares are voted at the special meeting by:

delivering written notice to our Corporate Secretary, Brian Adams, at our address above;

submitting a later dated proxy card; or

attending the special meeting and voting in person.

Table of Contents

Q. *Is my vote confidential?*

A. Yes. All votes remain confidential, unless you provide otherwise.

Q. *How are votes counted?*

A. Before the special meeting, our Board of Directors will appoint one or more inspectors of election for the meeting. The inspector(s) will determine the number of shares represented at the meeting, the existence of a quorum and the validity and effect of proxies. The inspector(s) will also receive, count, and tabulate ballots and votes and determine the results of the voting on each matter that comes before the special meeting.

Abstentions and shares represented by proxies reflecting abstentions will be treated as present for purposes of determining the existence of a quorum at the special meeting. Broker or nominee non-votes, which occur when shares held in street name by brokers or nominees who indicate that they do not have discretionary authority to vote on a particular matter, will not be considered as votes for or against that particular matter. Broker and nominee non-votes will be treated as present for purposes of determining the existence of a quorum, and may be entitled to vote on certain matters at the special meeting.

Q. *What constitutes a quorum at the special meeting?*

A. In accordance with Delaware law (the law under which we are incorporated) and our amended and restated bylaws, the presence at the special meeting, by proxy or in person, of the holders of a majority of the shares of our common stock outstanding on the record date constitutes a quorum, thereby permitting the stockholders to conduct business at the special meeting. Abstentions and broker or nominee non-votes will be included in the calculation of the number of shares considered present at the special meeting for purposes of determining the existence of a quorum.

If a quorum is not present at the special meeting, a majority of the stockholders present in person and by proxy may adjourn the meeting to another date. If an adjournment is for more than 30 days or a new record date is fixed for the adjourned meeting by our Board of Directors, we will provide notice of the adjourned meeting to each stockholder of record entitled to vote at the adjourned meeting. At any adjourned meeting at which a quorum is present, any business may be transacted that might have been transacted at the originally called meeting.

Q. *What vote is required to approve an amendment to our 2013 Incentive Plan to increase the number of authorized shares issuable thereunder from 3,500,000 to 9,500,000?*

A. The affirmative vote of a majority of the shares present, in person or by proxy, and entitled to vote at the special meeting is required to approve an amendment to our 2013 Incentive Plan to increase the number of authorized shares issuable thereunder from 3,500,000 to 9,500,000. Abstentions and shares represented by proxies reflecting abstentions will have the same effect as a negative vote. However, broker or nominee non-votes, and shares represented by proxies reflecting broker or nominee non-votes, will not have the effect of a vote against this

proposal as they are not considered to be present and entitled to vote on this matter.

Q. *What percentage of our outstanding common stock do our directors and executive officers own?*

- A. As of September 30, 2014, our directors and executive officers owned, or have the right to acquire, approximately 4.0% of our outstanding common stock. See the discussion under the heading *Stock Ownership of Our Directors, Executive Officers, and 5% Beneficial Owners* on page 22 for more details.

Table of Contents

Q. *How can I obtain a copy of our annual report on Form 10-K?*

- A. We have filed our annual report on Form 10-K for the year ended December 31, 2013, with the Securities and Exchange Commission. You may obtain, free of charge, a copy of our annual report on Form 10-K, including financial statements and exhibits, by writing to our corporate secretary, Brian Adams, or by email at info@keryx.com. Upon request, we will also furnish any exhibits to the annual report on Form 10-K as filed with the SEC.

Table of Contents

COMPENSATION DISCUSSION AND ANALYSIS

In the paragraphs that follow, we give an overview and analysis of our compensation program and policies, the material compensation decisions we have made under those programs and policies with respect to our executive officers, and the material factors that we considered in making those decisions. Later in this proxy statement under the heading Executive Compensation, you will find a series of tables containing specific information about the compensation earned or paid in 2013 to the following individuals, whom we refer to as our named executive officers, or NEOs:

Ron Bentsur, our Chief Executive Officer; and

James F. Oliviero, our Chief Financial Officer and Treasurer.

Compensation Philosophy and Objectives

Our compensation programs are designed to motivate our employees to work toward achievement of our corporate mission to create long-term sustained stockholder value by acquiring, developing and commercializing pharmaceutical products for the treatment of renal disease. Attaining our key business and strategic goals depends on attracting, retaining and motivating quality employees in an exceptionally competitive environment. Our industry is highly scientific, regulated, scrutinized and dynamic, and as a result, we require employees that are highly educated, dedicated and experienced. The driving philosophy and objectives behind our executive compensation programs are:

to attract, retain, motivate and reward outstanding employees;

to align employees' interests with those of our stockholders by creating a strong focus on stock ownership and basing pay on performance measures that drive long-term stockholder value;

to incentivize our employee to achieve our business goals; and

to reflect our pay for performance culture.

Determining Executive Compensation

Role of the Compensation Committee

The Compensation Committee oversees our executive compensation programs, including approving incentive programs, granting equity awards, and determining appropriate levels of compensation for our NEOs.

Role of the Executives

Our Chief Executive Officer develops recommendations regarding the compensation levels for our Chief Financial Officer based upon a subjective assessment of his individual performance during the prior year and overall trends in

the marketplace. In addition, each year, management delivers to the Compensation Committee a set of proposed corporate goals and objectives that management believes are essential to the achievement of the Company's mission and long-term goals and objectives. These recommendations and proposed goals and objectives are reviewed, modified if deemed appropriate, and approved by the Compensation Committee.

Table of Contents**Elements of Compensation**

Our executive compensation program for 2013 consisted of the following components:

Compensation Element	Purpose
Base salary	Base salary represents the fixed portion of an executive's annual compensation and is intended to recognize the executive's value to the Company based on skills and experience relative to the responsibilities of his position.
Annual cash incentive awards	Annual cash incentive awards represent the portion of an executive's compensation that is intended to vary as a direct reflection of Company and individual performance for the year. Mr. Bentsur's maximum annual incentive award was equal to 75% of his base salary, per the terms of his employment agreement. Mr. Oliviero's annual incentive award was determined in connection with the Company's annual incentive bonus pool, as described below.
Special bonus awards	The Compensation Committee decided to pay additional bonus amounts to our executive officers based upon the FDA's filing acceptance of the Company's New Drug Application for Ferric Citrate and our executive officers' performance for the year.
Long-term equity awards	Long-term equity awards are intended to reward performance over a multi-year period, link the interests of executives to those of the stockholders, and encourage retention. Restricted stock and stock options generally are issued based upon achievement of corporate goals and objectives in the prior year. In addition, Mr. Bentsur is eligible to receive grants of restricted stock pursuant to the performance thresholds provided in his employment agreement, with additional time-based vesting requirements.
Health and welfare plans and retirement plan	These benefits are intended to provide competitive levels of medical and disability coverage, and retirement benefits under our 401(k) plan. Our executives participate in the same programs offered to all of our eligible employees.
Severance benefits	Our Chief Executive Officer has an employment agreement that provides for severance benefits in certain circumstances and our Chief Financial Officer has a change-in-control agreement that provides for severance benefits in the event of a qualifying termination following a change in control of the Company.

No specific formula is used in regard to the allocation of the various elements within our executive compensation program. The Compensation Committee retains the discretion to reduce or eliminate the payment that otherwise might be payable to our executives based upon unforeseen events occurring during the year or its assessment of the Company's or our executives' performance in general.

In order to maximize the incentive effect of our compensation program, we have structured our performance-based compensation to involve a mix of value opportunities and performance measures.

Our annual cash incentive awards and our annual equity awards are based partially upon the Company's performance against pre-set corporate goals and objectives and partially upon the Compensation Committee's assessment of each individual executive's contribution to the Company's performance.

The ultimate realized value of our equity awards (stock options and restricted stock awards) is tied to our stock price, in alignment with our stockholders.

Consideration of Last Year's Advisory Stockholder Vote on Executive Compensation

At the 2013 Annual Meeting of Stockholders, approximately 96% of the shares represented and entitled to vote at the annual meeting were voted to approve the compensation of the Company's named executive officers,

Table of Contents

as discussed and disclosed in the 2013 Proxy Statement. In considering the results of this advisory vote on executive compensation, the Compensation Committee concluded that the compensation paid to our named executive officers and the Company's overall pay practices enjoy stockholder support.

In light of this support, the Compensation Committee decided to retain the core design of our executive compensation program, with an emphasis on short and long-term incentive compensation that rewards our senior executives when they successfully achieve our corporate goals and objectives and, in turn, deliver value for our shareholders. As described below, in 2013, the Compensation Committee decided to pay additional bonus amounts to our executive officers based upon the FDA's filing acceptance of the Company's New Drug Application for Ferric Citrate and our executive officers' performance for the year. In addition, in 2014, the Compensation Committee increased our executives' salaries and decreased our CEO's target incentive percentage, which it believes will provide a more competitive pay package when compared to the market median. Going forward, future advisory votes on executive compensation will serve as an additional tool to guide the Board of Directors and the Compensation Committee in evaluating the alignment of the Company's executive compensation program with the interests of the Company and its stockholders.

At the 2011 Annual Meeting of Stockholders, our stockholders expressed a preference that advisory votes on executive compensation be held on an annual basis. Consistent with this preference, the Board of Directors determined to implement an advisory vote on executive compensation on an annual basis until the next required vote on the frequency of stockholder votes on the compensation of executive officers, which is scheduled to occur at the 2017 annual meeting.

2013 Executive Compensation***2013 Corporate Performance Goals***

Our 2013 annual incentive awards were based, in large part, upon the achievement of corporate performance goals, which included a combination of clinical and regulatory goals related to our products as well as other corporate goals, and were achieved at an aggregate level of 100.0%. The corporate performance goals and objectives used to determine annual incentive awards in 2013 were as follows:

Various goals related to regulatory filings for Ferric Citrate 55.0% maximum potential weighting (55.0% achieved);

Various goals related to Ferric Citrate clinical studies 20.0% maximum potential weighting (20.0% achieved); and

Various goals related to Ferric Citrate manufacturing 25.0% maximum potential weighting (25.0% achieved).

The Compensation Committee considered performance against these goals in determining the amounts paid as annual incentive awards in 2013, as well as its subjective assessment of our executives' contributions to Company performance.

Base Salary

Mr. Bentsur's and Mr. Oliviero's base salaries for 2013 remained unchanged at \$300,000 and \$265,000, respectively.

Cash Incentive Awards

In 2013, Mr. Bentsur was eligible to earn an annual cash incentive of up to 75% of his base salary, per the terms of his employment agreement. Mr. Oliviero's annual incentive award was determined in connection with the Company's annual incentive bonus pool, as described below. Both executives' annual cash incentive awards

Table of Contents

were based upon the Company's performance against pre-established corporate goals and objectives, which are discussed above, and each executive's individual performance based upon subjective performance reviews. The actual amounts paid to the executives pursuant to their annual cash incentive awards are reported in the Summary Compensation Table as non-equity incentive plan compensation.

Mr. Bentsur's 2013 Annual Cash Incentive Award. As noted above, in 2013, Mr. Bentsur was eligible to earn an annual cash incentive of up to 75% of his base salary, per the terms of his employment agreement. Mr. Bentsur's annual cash incentive was based on achievement of the corporate goals and objectives (80% weighting), which was achieved at the 100% level, and on individual performance, based upon a subjective review by the Compensation Committee (20% weighting), which was achieved at the 100% level, resulting in a \$225,000 cash incentive payment (the maximum amount). In addition, based on its assessment of Mr. Bentsur's contribution to the Company's performance during 2013, the Compensation Committee granted Mr. Bentsur an additional \$75,000.

Additionally, during 2013, the Compensation Committee approved the grant of an incentive bonus to Mr. Bentsur in the amount of \$100,000, which was achieved upon the FDA's filing acceptance of the Company's New Drug Application for Ferric Citrate.

Annual Cash Incentive Award Pool and Mr. Oliviero's 2013 Annual Cash Incentive Award. In 2013, our employees, other than Mr. Bentsur, were eligible for annual cash incentives based on an overall annual cash incentive award pool calculated as the sum of our employees' salaries (excluding Mr. Bentsur) multiplied by a percentage set by the Compensation Committee for such year. In 2013, the percentage was set at 25%, resulting in a maximum cash incentive pay pool of \$885,071. For most of our employees, a component of their annual cash incentive is based on corporate goals and objectives and a component is based on individual performance. At the lowest level, employees only have an individual component. For 2013, the Compensation Committee used its discretion to increase the overall cash incentive award pool, and an aggregate of \$906,990 was distributed to employees, including Mr. Oliviero.

Mr. Oliviero's maximum 2013 annual cash incentive was determined to be 40% of his base salary. Mr. Oliviero was allocated 11.7% of the overall cash incentive award pool. His award was based on achievement of the corporate goals and objectives (60% weighting), which was achieved at the 100% level, and on individual performance, based upon a subjective review by the Chief Executive Officer and the Compensation Committee (40% weighting), which was achieved at the 100% level, resulting in a \$106,000 cash incentive payment (the maximum amount). In addition, based on its assessment of Mr. Oliviero's contribution to the Company's performance during 2013, the Compensation Committee granted Mr. Oliviero an additional \$40,000.

Additionally, during 2013, the Compensation Committee approved the grant of an incentive bonus to Mr. Oliviero in the amount of \$100,000, which was achieved upon the FDA's filing acceptance of the Company's New Drug Application for Ferric Citrate.

Long-Term Equity Incentive Awards

Mr. Bentsur. After consideration of our 2012 corporate goals and objectives, which were achieved at a 87.5% level, and a subjective consideration of Mr. Bentsur's individual performance during 2012, the Compensation Committee granted Mr. Bentsur, on January 2, 2013, an option to purchase 75,000 shares of our common stock and an award of 25,000 shares of restricted stock.

In addition, Mr. Bentsur's employment agreement provides that he has the opportunity to receive certain restricted stock awards upon the achievement of performance milestones. He received the first two restricted stock awards in 2009 and 2010, which we refer to as the Bentsur¹ Milestone Award and the Bentsur² Milestone Award,

respectively. Upon achievement of the second milestone, the Bentsur 1st Milestone Award was immediately vested. Mr. Bentsur did not receive any milestone awards in 2011 or 2012. On October 4, 2013,

Table of Contents

Mr. Bentsur received a third restricted stock award, which we refer to as the Bentsur 3rd Milestone Award, in connection with our filing of an accepted new drug application with the U.S. Food and Drug Administration for Ferric Citrate. Such restricted stock will vest in equal installments over each of the first three anniversaries of the grant date provided that Mr. Bentsur remains employed by us during such vesting period.

Mr. Bentsur's employment agreement, as amended, provides that he has the opportunity to receive the following additional milestone awards:

500,000 shares of fully-vested stock upon the first to occur of (a) our first commercial sale of Ferric Citrate in the U.S. off an approved NDA, (b) our receipt of the first royalty upon the commercial sale of Ferric Citrate in the U.S. by a partner to whom the Company has sold exclusive or non-exclusive commercial rights, or (c) our complete outlicensing of the entire product rights of Ferric Citrate in the U.S., which we refer to as the Bentsur 4th Milestone Award.

100,000 shares of restricted stock upon each event of our outlicensing Ferric Citrate in a foreign market, other than Japan, resulting in a greater than \$10 million non-refundable cash payment to the Company with a gross deal value to the Company of at least \$50 million, which we refer to as the Bentsur 5th Milestone Award. Such restricted stock will vest in equal installments over each of the first three anniversaries of the date of grant provided he remains employed by us during such vesting period.

Annual Equity Award Pool and Mr. Oliviero. In 2013, based upon performance during 2012, our employees, other than Mr. Bentsur, were eligible to receive long-term equity awards based on an overall annual equity award pool of 558,574 shares, calculated based upon 0.75% of an adjusted fully-diluted shares outstanding figure (74,476,501). Each employee was allocated a portion of the annual equity award pool which represented such employee's maximum potential grant. For most of our employees, a component of their annual equity award is based on corporate goals and objectives and a component is based on individual performance. At the lowest level, employees only have an individual component. In 2013 (based upon performance during 2012), options to purchase 315,366 shares of our common stock and awards of 236,020 shares of restricted stock were granted to employees from the annual equity award pool, including grants of 55,866 stock options and 33,520 restricted shares to Mr. Oliviero.

For additional information regarding our named executive officers' stock grants, see the Summary Compensation Table, the Grants of Plan-Based Awards Table and the Outstanding Equity Awards at 2013 Fiscal Year End table. Awards based upon consideration of 2013 performance were granted on January 2, 2014. Pursuant to SEC rules, these awards will appear in next year's proxy statement.

Perquisites and Other Executive Benefits

We do not offer our NEOs any perquisites or other executive benefits.

Severance Benefits

We have an employment agreement with Mr. Bentsur that provides, among other things, payment and benefits upon certain terminations of employment. We believe this agreement was an important component in our effort to recruit and retain a chief executive officer, particularly for a company at our stage of development and in our relatively high-risk industry. On June 11, 2013, we amended Mr. Bentsur's employment agreement to (i) extend the term of the agreement until May 20, 2015, (ii) increase the severance payable upon a termination without Cause or resignation for

Good Reason to 100% of his then-current base salary, (iii) extend the opportunity for certain unearned milestone opportunities to vest following certain terminations of employment, (iv) provide for immediate vesting of all stock options upon a change in control, (v) revise the definition of Commercial Sales Milestone to remove all references to Perifosine, and (vi) provide for the grant of fully-vested shares of common stock upon achievement of the Bentsur 4th Milestone Award, as set forth in the amendment.

Table of Contents

On October 31, 2011, we entered into a change-in-control agreement with Mr. Oliviero that provides certain payments and benefits upon his involuntary termination of employment within 12 months following a change in control. On June 10, 2013, we amended Mr. Oliviero's change-in-control agreement to extend the automatic termination date of the agreement to October 31, 2015.

The Board of Directors believes that the change in control benefits described above are in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication of Mr. Bentsur and Mr. Oliviero, notwithstanding the possibility, threat or occurrence of a change in control of the Company.

For more information on Mr. Bentsur's employment agreement, including the 2013 amendment, and Mr. Oliviero's change-in-control agreement, see the "Potential Payments upon Termination or Change-in-Control" section beginning on page 15 of this proxy statement.

2014 Executive Compensation

In 2014, the Compensation Committee engaged Radford, An Aon Hewitt Company, a compensation consultant, to conduct a comparative analysis of our executive compensation program, in relation to a group of 21 peer companies in the biotechnology industry. The analysis concluded that there was a significant misalignment of executive cash compensation as compared to the peer group, due primarily to no salary increases for the CEO and CFO for the last 5 years and 4 years, respectively. After considering this analysis, the Compensation Committee approved the following changes to Mr. Bentsur's and Mr. Oliviero's compensation for 2014, which are intended to make their total direct compensation (both cash and equity) more competitive with the peer group median:

Effective March 1, 2014, Mr. Bentsur's base salary was increased from \$300,000 to \$530,000, and his target cash incentive award for 2014 was reduced to be equal to up to 65% of his base salary; and

Effective March 1, 2014, Mr. Oliviero's base salary was increased from \$265,000 to \$365,000.

Report of the Compensation Committee

The Compensation Committee of the Board of Directors has reviewed and discussed with management the Compensation Discussion and Analysis set forth above. Based on the review and discussions noted above, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement and incorporated by reference in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, for filing with the SEC.

By the Compensation Committee of the Board of Directors

Kevin Cameron, Chairperson

Wyche Fowler, Jr.

Michael Tarnok

Table of Contents

RISK ASSESSMENT OF COMPENSATION PROGRAMS

The Compensation Committee has reviewed with management the design and operation of our incentive compensation arrangements for all employees, including executive officers, for the purpose of determining whether such programs might encourage inappropriate risk-taking that could have a material adverse effect on the Company. Management and the Compensation Committee reviewed the Company's incentive compensation arrangements for the purpose of identifying any aspects of such programs that might encourage behaviors that could exacerbate business risks. In conducting this assessment, the Compensation Committee considered, among other things, the performance objectives used in connection with these incentive awards and the features of the Company's compensation program that are designed to mitigate compensation-related risk. The Compensation Committee concluded that any risks arising from the Company's compensation plans, policies and practices are not reasonably likely to have a material adverse effect on the Company.

Table of Contents**EXECUTIVE COMPENSATION****Summary Compensation Table**

The following table sets forth the cash and other compensation that we paid to our named executive officers (NEOs) or that was otherwise earned by our NEOs for their services in all capacities during 2011, 2012 and 2013. For a description of the individual amounts indicated below, please see our Compensation Discussion and Analysis beginning on page 4 of this proxy statement.

Name and Principal Position	Year	Salary (\$)	Bonus (\$) ⁽¹⁾	Stock Awards (\$) ⁽²⁾	Option Awards (\$) ⁽²⁾	Non-Equity Incentive All Plan Other		Total (\$)
						Compen	Other	
Ron Bentsur	2013	300,000	175,000	4,205,500	144,525	225,000		5,050,025
Chief Executive Officer	2012	300,000		83,490	124,084	202,500		710,074
	2011	300,000		114,500	262,590	210,338		887,428
James F. Oliviero	2013	265,000	140,000	1,644,186	107,654	106,000		2,262,840
Chief Financial Officer,	2012	265,000		70,840	101,860	106,000		543,700
Treasurer and Corporate Secretary	2011	265,000		74,425	170,684	106,000		616,109

- (1) Reflects the \$100,000 bonus paid to each of the NEOs upon the first FDA acceptance of a New Drug Application submission, and an additional discretionary bonus in recognition of each of the NEOs' contribution to the Company's performance during 2013. Please see our Compensation Discussion and Analysis for more information.
- (2) Reflects the aggregate grant date fair value of stock and option awards granted by the Company as computed under FASB ASC Topic 718. The grant date fair value of the stock awards is based on the fair market value of the underlying shares on the date of grant and does not take into account any estimated forfeitures. The grant date fair value of the stock awards also does not take into account any stock awards which vest upon certain corporate milestones when the measurement date for accounting purposes for such awards has not yet occurred and the fair value is uncertain. For such awards, stock-based compensation is measured and recorded if and when a milestone occurs, and the compensation for such awards are reflected in the table in such year the compensation is recorded. The assumptions made in the valuation of the option awards are contained in Note 11 to our consolidated financial statements for 2013, 2012 and 2011, which are included in our Annual Report on Form 10-K for the fiscal year 2013, 2012 and 2011, respectively.

Grants of Plan-Based Awards For Fiscal Year 2013

The following table below sets forth the individual grants of awards made to each of our NEOs during 2013. For a description of the individual amounts indicated below, please see our Compensation Discussion and Analysis beginning on page 4 of this proxy statement.

Name	Grant Date	Estimated Future Payouts Under Non-Equity Incentive Plan Awards ⁽¹⁾			All Other	All Other	Exercise or Base Price of Option Awards (\$/sh)	Grant Date Fair Value of Awards (\$) ⁽⁴⁾
		Threshold (\$)	Target (\$)	Maximum (\$)	Stock Awards: Number of Shares of Stock or Units (#) ⁽²⁾	Option Awards: Number of Securities Underlying Options (#) ⁽³⁾		
Mr. Bentsur			225,000					
	01/02/13				25,000		69,500	
	01/02/13					75,000	2.78	
	10/04/13				400,000		4,136,000	
Mr. Oliviero			106,000					
Depreciation, amortization and accretion, net	(4,563)	(2,111)						
Provision for loan and lease losses	6,110	2,770						
Income from bank-owned life insurance	(906)	(783)						
Share-based compensation expense	80	287						
Net gains on lease sales	(26)	(287)						
Gain on sale of available for sale securities	(61)	(410)						
Credit component of other-than-temporary impairment losses on available for sale securities	70	219						
Gain on sale of other real estate owned	(38)							
Proceeds from sales of leases	976	9,538						
Leases originated for sale	(794)	(5,985)						
Decrease in accrued interest receivable	414	893						
Decrease (increase) in prepaid expenses and other assets	188	(267)						
Decrease in other liabilities	(1,724)	(2,381)						

Net cash provided by operating activities	4,132	8,374
Cash flows from investing activities:		
Available for sale securities:		
Purchases	(163,639)	(116,892)
Maturities and principal repayments	126,490	91,112
Proceeds from sales	1,880	22,548
Net increase in loans and leases	(39,631)	(24,048)
Capital expenditures for premises and equipment	(965)	(538)
Proceeds from sale of other real estate owned	988	
Purchase of Federal Home Loan Bank of Boston stock	(603)	
Net cash used in investing activities	(75,480)	(27,818)
Cash flows from financing activities:		
Net increase in deposits	49,739	7,374
Net decrease in overnight and short-term borrowings	(8,645)	(11,019)
Proceeds from long-term borrowings	80,791	43,400
Repayment of long-term borrowings	(52,080)	(25,222)
Exercise of stock options	439	555
Repurchase of warrant	(1,400)	
Redemption of preferred stock	(30,000)	
Repurchase of common stock	(254)	(1,866)
Tax benefit from exercise of stock options	81	189

Dividends on preferred stock	(892)	
Dividends on common stock	(2,345)	(2,224)
Net cash provided by financing activities	35,434	11,187
Net decrease in cash and cash equivalents	(35,914)	(8,257)
Cash and cash equivalents at beginning of period	55,457	37,562
Cash and cash equivalents at end of period	\$ 19,543	\$ 29,305

Supplementary Disclosures:		
Cash paid for interest	\$ 21,789	\$ 29,067
Cash paid for income taxes	2,404	3,150
Non-cash investing and financing transactions:		
Change in accumulated other comprehensive income, net of taxes	3,084	(3,370)
Cumulative effect of a change in accounting principle, net of taxes	137	
Contingent share payments related to Macrolease acquisition	78	656
Transfer of loans to other real estate owned	2,083	352
Treasury stock acquisitions from shares tendered in stock option exercises	254	

See accompanying notes to unaudited consolidated financial statements

Table of Contents

BANCORP RHODE ISLAND, INC.

Notes to Consolidated Financial Statements (unaudited)

(1) Basis of Presentation

Bancorp Rhode Island, Inc. (the Company), a Rhode Island corporation, is the holding company for Bank Rhode Island (the Bank). The Company has no significant assets other than the common stock of the Bank. For this reason, substantially all of the discussion in this Quarterly Report on Form 10-Q relates to the operations of the Bank and its subsidiaries.

In preparing the consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the balance sheet and revenues and expenses for the period. These estimates and assumptions are based on management's estimates and judgment and are evaluated on an ongoing basis using historical experiences and other factors, including the current economic environment. Estimates and assumptions are adjusted when facts and circumstances dictate. A recessionary environment, illiquid credit markets and declines in consumer spending have combined to increase the uncertainty inherent in management's estimates and assumptions. As future events cannot be determined with precision, actual results could differ significantly from management's estimates. Material estimates that are particularly susceptible to change relate to the determination of the allowance for loan and lease losses, evaluation of investments for other-than-temporary impairment, review of goodwill for impairment and income taxes.

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Bank Rhode Island, along with the Bank's wholly-owned subsidiaries, BRI Investment Corp. (a Rhode Island passive investment company), Macrolease Corporation (an equipment leasing company), Acorn Insurance Agency, Inc. (a licensed insurance agency) and BRI Realty Corp. (a real estate holding company). All significant intercompany accounts and transactions have been eliminated in consolidation.

The unaudited interim consolidated financial statements of the Company conform to U.S. generally accepted accounting principles and prevailing practices within the banking industry and include all necessary adjustments (consisting of only normal recurring adjustments) that, in the opinion of management, are required for a fair presentation of the results and financial condition of the Company. Prior period amounts are reclassified whenever necessary to conform to the current year classifications. The Company made a reclassification adjustment at December 31, 2008 from additional paid-in capital to preferred stock to reflect the liquidation value of shares of \$30.0 million, less the discount in preferred stock of \$1.4 million, in connection with the Company's participation in the U.S. Treasury's Capital Purchase Program. The result of the reclassification was an increase of \$28.6 million to preferred stock with a corresponding decrease to additional paid-in capital. This reclassification did not have an effect on previously reported net income or total shareholders' equity.

The Company considers events or transactions that occur after the balance sheet date but before the consolidated financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through November 4, 2009, the date of the issuance of these consolidated financial statements.

The unaudited interim results of consolidated operations are not necessarily indicative of the results for any future interim period or for the entire year. These interim consolidated financial statements do not include all disclosures associated with annual financial statements and, accordingly, should be read in conjunction with the annual consolidated financial statements and accompanying notes included in the Company's 2008 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC).

(2) Earnings Per Share

Basic earnings per share (EPS) excludes dilution and is computed by dividing net income available to common shareholders by the weighted average number of common shares and participating securities outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of additional common stock that then share in the earnings of the Company.

Table of Contents**(3) Recently Adopted Accounting Pronouncements**

In June 2009, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 168, *The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles* a replacement of FASB Statement No. 162 (FASB Accounting Standards Codification (ASC) 105-10). With the issuance of SFAS No. 168 (ASC 105-10), the ASC became the single source of authoritative U.S. accounting and reporting standards applicable for all nongovernmental entities, with the exception of guidance issued by the SEC. SFAS No. 168 (ASC 105-10) is effective for financial statements issued for interim or annual periods ending after September 15, 2009. Technical references to generally accepted accounting principles (GAAP) included in the notes to the Company s consolidated financial statements are provided using the terminology at the time of issuance. If the literature was not issued under the new ASC, parenthetical references to the ASC topic are provided. The Company expects that all references to pre-codification literature will be eliminated from its consolidated financial statements on January 1, 2010 upon the adoption of guidance that was issued prior to the ASC.

In December 2007, the FASB issued SFAS No. 141(R), *Business Combinations (Revised 2007)* (ASC 805-10). SFAS 141(R) replaces SFAS No. 141, *Business Combinations*, and applies to all transactions and other events in which one entity obtains control over one or more other businesses. SFAS 141(R) (ASC 805-10) requires an acquirer, upon initially obtaining control of another entity, to recognize the assets, liabilities and any non-controlling interest in the acquiree at fair value as of the acquisition date. Contingent consideration is required to be recognized and measured at fair value on the date of acquisition rather than at a later date when the amount of that consideration may be determinable beyond a reasonable doubt. This fair value approach replaces the cost-allocation process required under SFAS No. 141 whereby the cost of an acquisition was allocated to the individual assets acquired and liabilities assumed based on their estimated fair value. SFAS 141(R) (ASC 805-10) requires acquirers to expense acquisition-related costs as incurred rather than allocating such costs to the assets acquired and liabilities assumed, as was previously the case under SFAS No. 141. Under SFAS 141(R) (ASC 805-10), the requirements of SFAS No. 146, *Accounting for Costs Associated with Exit or Disposal Activities*, (ASC 420-10) would have to be met in order to accrue for a restructuring plan in purchase accounting. Pre-acquisition contingencies are to be recognized at fair value, unless it is a non-contractual contingency that is not likely to materialize, in which case, nothing should be recognized in purchase accounting and, instead, that contingency would be subject to the probable and estimable recognition criteria of SFAS No. 5, *Accounting for Contingencies* (ASC 450-10). The adoption of SFAS 141(R) (ASC 805-10) on January 1, 2009 did not have a material impact on the Company s consolidated financial statements.

In December 2007, the FASB issued SFAS No. 160, *Noncontrolling Interests in Consolidated Financial Statements an amendment of ARB No. 51* (ASC 810-10). SFAS No. 160 (ASC 810-10) establishes new accounting and reporting standards for the noncontrolling interest in a subsidiary. The adoption of SFAS No. 160 (ASC 810-10) on January 1, 2009 did not have a material impact on the Company s consolidated financial statements.

In March 2008, the FASB issued SFAS No. 161, *Disclosures about Derivative Instruments and Hedging Activities an amendment of FASB Statement No. 133* (ASC 815-10). SFAS No. 161 (ASC 815-10) changes the disclosure requirements for derivative instruments and hedging activities. Entities are required to provide enhanced disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS No. 133, *Accounting for Derivative Instruments and Hedging Activities*, (ASC 815-10) and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity s financial position, financial performance and cash flows. See *Note 6 Derivatives*.

Table of Contents

In June 2008, the FASB issued Staff Position (FSP) No. EITF 03-6-1, *Determining Whether Instruments Granted In Share-Based Payment Transactions Are Participating Securities* (ASC 260-10). FSP No. EITF 03-6-1 (ASC 260-10) concludes that unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and must be included in the computation of basic earnings per share using the two-class method. The Company grants restricted stock which includes nonforfeitable rights to dividends. Accordingly, unvested restricted stock awards are considered participating securities and were included in the earnings per share calculation. The adoption of this FSP on January 1, 2009 did not have a material impact on earnings per share or any impact on financial position or results of operations.

In April 2009, the FASB issued FSP No. FAS 141(R)-1, *Accounting for Assets Acquired and Liabilities Assumed in a Business Combination That Arise from Contingencies* (ASC 805-20). This FSP deals with the initial recognition and measurement of an asset acquired or a liability assumed in a business combination that arises from a contingency provided the asset or liability's fair value on the date of acquisition can be determined. This FSP is effective for assets and liabilities from contingencies in business combinations that occur following the start of the first fiscal year that begins on or after December 15, 2008. The adoption of this FSP on January 1, 2009 did not have a material impact on the Company's consolidated financial statements.

In April 2009, the FASB issued FSP No. FAS 157-4, *Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly* (ASC 820-10). FSP No. FAS 157-4 (ASC 820-10) provides guidelines for a broad interpretation of when to apply market-based fair value measurements. The FSP reaffirms management's need to use judgment to determine when a market that once was active has become inactive and in determining fair values in markets that are no longer active. The adoption of this FSP on April 1, 2009 impacted the method by which the Company determines fair value of its financial assets. Additionally, the adoption of this FSP expanded the disclosures relating to available for sale securities in the notes to the Company's consolidated financial statements. See *Note 7 Fair Value of Financial Instruments*.

In April 2009, the FASB issued FSP No. FAS 115-2 and FAS 124-2, *Recognition and Presentation of Other-Than-Temporary Impairments* (ASC 320-10) to amend the other-than-temporary impairment criteria associated with marketable debt securities and beneficial interests in securitized financial assets. This FSP requires that an entity evaluate for and record an other-than-temporary impairment when it concludes that it does not intend to sell an impaired security and does not believe it likely that it will be required to sell the security before recovery of the amortized cost basis. Once an entity has determined that an other-than-temporary impairment has occurred, it is required to record the credit loss component of the difference between the security's amortized cost basis and the estimated fair value in earnings, whereas the remaining difference is to be recognized as a component of other comprehensive income and amortized over the remaining life of the security. The FSP also requires some additional disclosures regarding expected cash flows, credit losses and an aging of securities with unrealized losses. The adoption of this FSP on April 1, 2009 expanded the disclosures relating to available for sale securities in the notes to the Company's consolidated financial statements. Additionally, the adoption of this FSP resulted in the reversal of a previously recognized other-than-temporary impairment through the Company's retained earnings and accumulated other comprehensive income and impacted the results and presentation of an other-than-temporary impairment loss. See *Note 5 Available for Sale Securities*.

In April 2009, the FASB issued FSP No. FAS 107-1 and APB 28-1, *Interim Disclosures about Fair Value of Financial Instruments* (ASC 825-10). The FSP increases the frequency of fair value disclosures to a quarterly instead of annual basis. The guidance relates to fair value disclosures for any financial instruments that are not currently reflected on the balance sheet at fair value. The adoption of this FSP expanded the disclosures relating to fair value of financial instruments in the notes to the Company's consolidated financial statements. See *Note 7 Fair Value of Financial Instruments*.

In May 2009, the FASB issued SFAS No. 165, *Subsequent Events* (ASC 855-10). SFAS No. 165 (ASC 855-10) provides authoritative accounting literature for events that occur subsequent to the balance sheet date of a company's financial statements. The guidance that SFAS No. 165 (ASC 855-10) provides is largely similar to current guidance in auditing literature, but directs responsibility at management for accounting and disclosure of subsequent events. The adoption of SFAS No. 165 (ASC 855-10) on June 30, 2009 did not have a material impact on the Company's

consolidated financial statements.

Table of Contents

(4) Recent Accounting Pronouncements

In June 2009, the FASB issued SFAS No. 166, *Accounting for Transfers of Financial Assets, an amendment of FASB Statement No. 140* (ASC 860-10). SFAS No. 166 (ASC 860-10) eliminates the concept of a qualifying special-purpose entity (QSPE) from SFAS No. 140, *Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities* (ASC 860-10), creates more stringent conditions for reporting a transfer of a portion of financial assets as a sale, clarifies other sale-accounting criteria and changes the initial measurement of a transferor's interest in transferred financial assets. SFAS No. 166 (ASC 860-10) also requires enhanced interim and year-end disclosures about a transferor's continuing involvement with transfers of financial assets accounted for as sales, the risks inherent in the transferred financial assets that have been retained and the nature and financial effect of restrictions on the transferor's assets that continue to be reported in the balance sheet. SFAS No. 166 (ASC 860-10) is effective for fiscal years and interim reporting periods within those fiscal years beginning after November 15, 2009. The Company is currently evaluating the impact that the adoption of SFAS No. 166 (ASC 860-10) may have on the Company's consolidated financial statements.

In June 2009, the FASB issued SFAS No. 167, *Amendments to FASB Interpretation No. 46(R)* (ASC 810-10). SFAS No. 167 (ASC 810-10) addresses the effects of eliminating the QSPE concept from SFAS No. 140 (ASC 860-10), changes the approach to determining the primary beneficiary of a variable interest entity (VIE) and requires companies to more frequently assess whether a VIE must be consolidated. SFAS No. 167 (ASC 810-10) also requires enhanced interim and year-end disclosures about the significant judgments and assumptions considered in determining whether a VIE must be consolidated, the nature of restrictions on a consolidated VIE's assets, the risks associated with a company's involvement with a VIE and how that involvement affects the company's financial position, financial performance and cash flows. SFAS No. 167 (ASC 810-10) is effective for fiscal years and interim reporting periods within those fiscal years beginning after November 15, 2009. The Company is currently evaluating the impact that the adoption of SFAS No. 167 (ASC 810-10) may have on the Company's consolidated financial statements.

(5) Available for Sale Securities

The Company categorizes available for sale securities by major category. Major categories are determined by the nature and risks of the securities and consider, among other things, the issuing entity, type of investment and underlying collateral. The Company categorizes securities issued by the Federal Home Loan Bank, Federal Home Loan Mortgage Corporation, Federal National Mortgage Association and Federal Farm Credit Banks Funding Corporation as government sponsored enterprise (GSE) securities.

Table of Contents

A summary of available for sale securities by major categories follows:

	Amortized Cost (1)	Unrealized Gains Losses		Fair Value
		(In thousands)		
At September 30, 2009:				
GSE obligations	\$ 80,957	\$ 481	\$ (43)	\$ 81,395
Trust preferred collateralized debt obligations	2,864		(2,379)	485
Collateralized mortgage obligations	49,626	714	(2,155)	48,185
GSE mortgage-backed securities	227,711	7,953	(23)	235,641
Total	\$ 361,158	\$ 9,148	\$ (4,600)	\$ 365,706
At December 31, 2008:				
U.S. Treasury obligations	\$ 9,990	\$	\$ (2)	\$ 9,988
GSE obligations	47,131	256		47,387
Corporate debt securities	2,001		(14)	1,987
Trust preferred collateralized debt obligations	2,735		(1,255)	1,480
Collateralized mortgage obligations	62,909	256	(2,415)	60,750
GSE mortgage-backed securities	201,001	4,289	(476)	204,814
Total	\$ 325,767	\$ 4,801	\$ (4,162)	\$ 326,406

(1) Amortized cost is net of write-downs as a result of other-than-temporary impairment.

The following table sets forth certain information regarding temporarily impaired investment securities:

	Less than One Year Fair Unrealized Value Losses		One Year or Longer Fair Unrealized Value Losses		Total Fair Unrealized Value Losses	
	(In thousands)					
At September 30, 2009:						
GSE obligations	\$ 19,943	\$ (43)	\$	\$	\$ 19,943	\$ (43)
Trust preferred collateralized debt obligations			485	(2,379)	485	(2,379)
Collateralized mortgage obligations	9,075	(210)	16,397	(1,945)	25,472	(2,155)
GSE mortgage-backed securities	13,668	(21)	331	(2)	13,999	(23)
Total	\$ 42,686	\$ (274)	\$ 17,213	\$ (4,326)	\$ 59,899	\$ (4,600)

At December 31, 2008:

U.S. Treasury obligations	\$ 9,988	\$ (2)	\$	\$	\$ 9,988	\$ (2)
Corporate debt securities	1,987	(14)			1,987	(14)
Trust preferred collateralized debt obligations			1,480	(1,255)	1,480	(1,255)
Collateralized mortgage obligations	30,771	(1,385)	10,343	(1,030)	41,114	(2,415)
GSE mortgage-backed securities	33,016	(350)	2,662	(126)	35,678	(476)
Total	\$ 75,762	\$ (1,751)	\$ 14,485	\$ (2,411)	\$ 90,247	\$ (4,162)

Table of Contents

The following table sets for the maturities of available for sale securities:

	Within One Year		After One, But Within Five Years		After Five, But Within Ten Years		After Ten Years	
	Amortized Cost	Fair Value	Amortized Cost	Fair Value	Amortized Cost	Fair Value	Amortized Cost	Fair Value
(In thousands)								
At September 30, 2009:								
GSE obligations	\$	\$	\$ 75,960	\$ 76,412	\$ 4,998	\$ 4,983	\$	\$
Trust preferred collateralized debt obligations							2,864	485
Collateralized mortgage obligations					25,268	24,850	24,357	23,335
GSE mortgage-backed securities					21,667	22,849	206,045	212,792
Total	\$	\$	\$ 75,960	\$ 76,412	\$ 51,933	\$ 52,682	\$ 233,266	\$ 236,612
At December 31, 2008:								
U.S. Treasury obligations	\$ 9,990	\$ 9,988	\$	\$	\$	\$	\$	\$
GSE obligations	5,000	5,013	42,131	42,374				
Corporate debt securities	2,001	1,987						
Trust preferred collateralized debt obligations							2,735	1,480
Collateralized mortgage obligations					20,867	20,408	42,042	40,343
GSE mortgage-backed securities					25,764	26,604	175,237	178,209
Total	\$ 16,991	\$ 16,988	\$ 42,131	\$ 42,374	\$ 46,631	\$ 47,012	\$ 220,014	\$ 220,032

At September 30, 2009 and December 31, 2008, respectively, \$280.7 million and \$272.9 million of available for sale securities were pledged as collateral for repurchase agreements, municipal deposits, Treasury Tax and Loan deposits, swap agreements, current and future Federal Home Loan Bank of Boston (FHLB) borrowings and future Federal Reserve discount window borrowings.

The Company performs regular analysis on the available for sale securities portfolio to determine whether a decline in fair value indicates that an investment is other-than-temporarily impaired. In making these other-than-temporary determinations, management considers, among other factors, the length of time and extent to which the fair value has been less than amortized cost, projected future cash flows, credit subordination and the creditworthiness, capital adequacy and near-term prospects of the issuers. Management also considers the Company's capital adequacy, interest rate risk, liquidity and business plans in assessing whether it is more likely than not that the Company will sell or be required to sell the securities before recovery.

If the Company determines that a decline in fair value is other-than-temporary and that it is more likely than not that the Company will not sell or be required to sell the security before recovery of its amortized cost, the credit portion of

the impairment loss is recognized in earnings and the noncredit portion is recognized in accumulated comprehensive income. The credit portion of the other-than-temporary impairment represents the difference between the amortized cost and the present value of the expected future cash flows of the security. If the Company determines that a decline in fair value is other-than-temporary and it will more likely than not sell or be required to sell the security before recovery of its amortized cost, the entire difference between the amortized cost and the fair value of the security will be recognized in earnings.

In performing the analysis for the two collateralized debt obligations (CDO A and CDO B) held by the Company, which are backed by pools of trust preferred securities, future cash flow scenarios for each security were estimated based on varying levels of severity for assumptions of future delinquencies, recoveries and prepayments. These estimated cash flow scenarios were used to determine whether the Company expects to recover the amortized cost basis of the securities. Projected credit losses were compared to the current level of credit enhancement to assess whether the security is expected to incur losses in any future period and therefore become other-than-temporarily impaired.

Upon adoption of FSP No. FAS 115-2 and FAS 124-2 (ASC 320-10) in the second quarter of 2009, management reevaluated the other-than-temporary impairment that was previously recognized on CDO A at September 30, 2008. Management determined that it did not meet the criteria for other-than-temporary impairment as defined by FSP No. FAS 115-2 and FAS 124-2 (ASC 320-10) because the amortized cost basis of the security was expected to be recovered, management had no intent to sell the security before recovery and it was more likely than not that the Company would not be required to sell the security before recovery. As a result, an adjustment of \$137,000, representing the previously recognized other-than-temporary impairment charge, net of accretion recognized on impairment and tax effects, has been applied to the opening balance of retained earnings with a corresponding adjustment to accumulated other comprehensive income.

Table of Contents

During September 2009, CDO A experienced an additional \$10.0 million in defaulting collateral. Projected credit loss severity assumptions were increased in estimated future cash flow scenarios and it was determined that management does not expect to recover \$70,000 of the security's amortized cost. In accordance with FSP No. FAS 115-2 and FAS 124-2 (ASC 320-10), the Company recorded an other-than-temporary impairment totaling \$696,000, representing the difference between the security's fair value and book value. The portion deemed to be credit related of \$70,000 has been recorded as a reduction to noninterest income, while the non-credit portion of \$626,000 has been recorded as a reduction of other comprehensive income. Management will continue to monitor this security for further potential impairment.

The following table provides a reconciliation of the beginning and ending balances for credit losses on debt securities for which a portion of an other-than-temporary impairment was recognized in other comprehensive income:

<i>(In thousands)</i>	Credit Component of Other-Than-Temporary Impairment Losses For Which a Portion Was Recognized in Other Comprehensive Income	
	2009	2008
Balance, January 1	\$	\$
Credit losses for which an other-than-temporary impairment was not previously recognized in other comprehensive income	(70)	
Balance, September 30	\$ (70)	\$

The following tables set forth information regarding the impact of the adoption of FSP No. FAS 115-2 and FAS 124-2 (ASC 320-10) on net income, net income applicable to common shares and earnings per share for the three and nine month periods ended September 30, 2009:

<i>(In thousands)</i>	Three Months Ended September 30, 2009	Nine Months Ended September 30, 2009
	<i>Net Income and Net Income Applicable to Common Shares</i>	
Net income	\$ 2,203	\$ 4,406
Non-credit component of other-than-temporary impairment losses adjusted for previously recognized other-than-temporary losses, net of taxes	(269)	(269)
Pro forma net income	1,934	4,137
Preferred stock dividends	(142)	(892)
Prepayment charges and accretion of preferred stock discount	(1,282)	(1,405)
Pro forma net income applicable to common shares	\$ 510	\$ 1,840

Table of Contents

	Three Months Ended September 30, 2009	Nine Months Ended September 30, 2009
	<i>Earnings Per Share - Basic</i>	
Earnings per share basic	\$ 0.17	\$ 0.46
Per share effect of non-credit component of other-than-temporary impairment losses adjusted for previously recognized other-than-temporary losses, net of taxes	(0.06)	(0.06)
Pro forma earnings per share basic	\$ 0.11	\$ 0.40
	Three Months Ended September 30, 2009	
	Nine Months Ended September 30, 2009	
	<i>Earnings Per Share - Diluted</i>	
Earnings per share diluted	\$ 0.17	\$ 0.46
Per share effect of non-credit component of other-than-temporary impairment losses adjusted for previously recognized other-than-temporary losses, net of taxes	(0.06)	(0.06)
Pro forma earnings per share diluted	\$ 0.11	\$ 0.40

Management reviewed CDO B and assessed the issuer's ability to continue to make principal and interest payments. The Company did not receive its September interest payment because the security is adding interest to the principal rather than paying out. However, management reviewed various cash flow scenarios driven by varying assumptions (including default rates and recoveries) for this instrument and determined that although current and future deferrals and defaults may cause a temporary break in interest payments, management expects to recover the amortized cost of the security due to the structure of the instrument. The structure is such that payments to all junior subordinated tranches of the instrument (of which there are two) are diverted to senior level tranches until they meet certain over-collateralization tests. Essentially, the senior level tranches will continue to be paid until there are no further funds available from the junior tranches. Because management expects to recover the amortized cost of the security and it is more likely than not that the security will not be sold or be required to be sold before recovery, no other-than-temporary impairment exists at September 30, 2009.

The decline in fair value of the remaining available for sale securities in an unrealized loss position is due to a substantial widening of interest rate spreads across market sectors related to the continued illiquidity and uncertainty of the securities markets. Management believes that it will recover the amortized cost basis of the securities and that it is more likely than not that it will not be required to sell the securities before recovery. Additionally, management has no intent to sell the securities before recovery. As such, management has determined that the securities are not other-than-temporarily impaired as of September 30, 2009. If market conditions for securities worsen or the

creditworthiness of the underlying issuers deteriorates, it is possible that the Company may recognize additional other-than-temporary impairments in future periods.

(6) Derivatives

All derivatives are recognized as either assets or liabilities on the balance sheet and are measured at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative and resulting designation. Derivatives used to hedge the exposure to changes in fair value of an asset, liability or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives used to hedge the exposure to variability in expected cash flows or other types of forecasted transactions are considered cash flow hedges. For derivatives designated as fair value hedges, changes in the fair value of the derivative are recognized in earnings together with the changes in the fair value of the related hedged item. The net amount, if any, representing hedge ineffectiveness, is reflected in earnings. For derivatives designated as cash flow hedges, the effective portion of changes in the fair value of the derivative is recorded in other comprehensive income and recognized in earnings when the hedged transaction affects earnings. The ineffective portion of changes in the fair value of cash flow hedges is recognized directly in earnings. For derivatives not designated as hedges, changes in fair value are recognized in earnings, in noninterest income. The Company may use interest rate contracts (swaps, caps and floors) as part of interest rate risk management strategy. Interest rate swap, cap and floor agreements are entered into as hedges against future interest rate fluctuations on specifically identified assets or liabilities. The Company did not have derivative fair value or derivative cash flow hedges at September 30, 2009 or December 31, 2008.

Table of Contents

The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the consolidated balance sheets as of September 30, 2009 and December 31, 2008:

	Asset Derivatives			Liability Derivatives		
	Balance Sheet Location	As of September 30, 2009	As of December 31, 2008	Balance Sheet Location	As of September 30, 2009	As of December 31, 2008
<i>(In thousands)</i>						
			Fair Value			Fair Value
Derivatives not designated as hedging instruments						
Interest rate products	Other assets	\$ 471	\$ 482	Other liabilities	\$ 477	\$ 431
Total derivatives not designated as hedging instruments		\$ 471	\$ 482		\$ 477	\$ 431

Derivatives not designated as hedges are not speculative and result from a service the Company provides to certain customers for a fee. The Company executes interest rate swaps with commercial banking customers to aid them in managing their interest rate risk. The interest rate swap contracts allow the commercial banking customers to convert floating rate loan payments to fixed rate loan payments. The Company concurrently enters into mirroring swaps with a third party financial institution, effectively minimizing its net risk exposure resulting from such transactions. The third party financial institution exchanges the customer's fixed rate loan payments for floating rate loan payments. As the interest rate swaps associated with this program do not meet hedge accounting requirements, changes in the fair value of both the customer swaps and the offsetting swaps are recognized directly in earnings. As of September 30, 2009, the Company had ten interest rate swaps with an aggregate notional amount of \$35.8 million related to this program. During the three and nine months ended September 30, 2009, the Company recognized net losses of \$63,000 and \$57,000 respectively, related to changes in the fair value of these swaps. The Company did not have interest rate swap contracts at September 30, 2008.

Table of Contents

The table below presents the effect of the Company's derivative financial instruments on the consolidated income statements for the three months ended September 30, 2009 and 2008:

Derivatives Not Designated as Hedging Instruments	Location of Gain or (Loss) Recognized in Income on Derivative	Amount of Gain or (Loss) Recognized in Income on Derivative ⁽¹⁾ Three Months Ended September 30,	
		2009	2008
		<i>(In thousands)</i>	
Interest Rate Products	Loan related fees	\$ (63)	\$
Total		\$ (63)	\$

(1) The amount of gain recognized in income represents net fee income and changes related to the fair value of the interest rate products.

The table below presents the effect of the Company's derivative financial instruments on the consolidated income statements for the nine months ended September 30, 2009 and 2008:

Derivatives Not Designated as Hedging Instruments	Location of Gain or (Loss) Recognized in Income on Derivative	Amount of Gain or (Loss) Recognized in Income on Derivative ⁽¹⁾ Nine Months Ended September 30,	
		2009	2008
		<i>(In thousands)</i>	
Interest Rate Products	Loan related fees	\$ 259	\$
Total		\$ 259	\$

(1) The amount of gain recognized

in income
represents net
fee income and
changes related
to the fair value
of the interest
rate products.

By using derivative financial instruments, the Company exposes itself to credit risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative is negative, the Company owes the counterparty and, therefore, it does not possess credit risk. The credit risk in derivative instruments is mitigated by entering into transactions with highly-rated counterparties that management believes to be creditworthy and by limiting the amount of exposure to each counterparty. At September 30, 2009, the Company does not expect future nonperformance by counterparties.

Certain of the derivative agreements contain provisions that require the Company to post collateral if the derivative exposure exceeds a threshold amount. As of September 30, 2009, the Company has posted collateral of \$470,000 in the normal course of business.

The Company has agreements with certain of its derivative counterparties that contain credit-risk-related contingent provisions. These provisions provide the counterparty with the right to terminate its derivative positions and require the Company to settle its obligations under the agreements if the Company defaults on certain of its indebtedness or if the Company fails to maintain its status as a well-capitalized institution. As of September 30, 2009, the Company had no derivative agreements in a net liability position, excluding fair value adjustments for credit risk.

Table of Contents**(7) Fair Value of Financial Instruments**

In September 2006, the FASB issued SFAS No. 157, *Fair Value Measurements* (ASC 820-10). SFAS No. 157 (ASC 820-10) provides guidance for measuring assets and liabilities at fair value. In February 2008, the FASB issued FSP No. FAS 157-2, *Effective Date of FASB Statement No. 157* (ASC 820-10-65). This FSP delayed the effective date of SFAS No. 157 (ASC 820-10) for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value on a recurring basis (at least annually), to fiscal years beginning after November 15, 2008 and interim periods within those fiscal years. The adoption of FSP No. FAS 157-2 (ASC 820-10-65) on January 1, 2009 did not have a material impact on the Company's consolidated financial statements.

SFAS No. 157 (ASC 820-10) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. The price in the principal (or most advantageous) market used to measure the fair value of the asset or liability is adjusted for transaction costs. An orderly transaction is a transaction that assumes exposure to the market for a period prior to the measurement date to allow for marketing activities that are usual and customary for transactions involving such assets and liabilities. Market participants are buyers and sellers in the principal market that are independent, knowledgeable, able to transact and willing to transact.

SFAS No. 157 (ASC 820-10) requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets and liabilities. The income approach uses valuation techniques to convert future amounts, such as cash flows or earnings, to a single present amount on a discounted basis. The cost approach is based on the amount that currently would be required to replace the service capacity of an asset (replacement cost). Valuation techniques should be consistently applied. Inputs to valuation techniques refer to the assumptions that market participants would use in pricing the asset or liability. Inputs may be observable, meaning those that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from independent sources, or unobservable, meaning those that reflect the reporting entity's own assumptions about what assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. SFAS No. 157 (ASC 820-10) establishes a fair value hierarchy for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:

Level 1: Inputs are unadjusted quoted prices in active markets for assets or liabilities identical to those reported at fair value.

Level 2: Inputs other than quoted prices included within Level 1, Level 2 inputs are observable either directly or indirectly. These inputs include quoted prices in active or not active markets or inputs derived from or corroborated by observable market data.

Level 3: Inputs are unobservable inputs for an asset or liability. These inputs are used to determine fair value only when observable inputs are not available.

Table of Contents

The following tables summarize the financial assets and financial liabilities measured at fair value on a recurring basis as of September 30, 2009 and December 31, 2008, segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value:

**Fair Value Measurements at September 30, 2009
Using**

<i>(In thousands)</i>	Total	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)	
GSE obligations	\$ 81,395	\$	\$	81,395	\$	
Trust preferred CDOs	485			485		
Collateralized mortgage obligations	48,185			48,185		
GSE mortgage-backed securities	235,641			235,641		
Total available for sale securities	365,706			365,706		
Interest rate swap assets	471			471		
Interest rate swap liabilities	477			477		

**Fair Value Measurements at December 31, 2008
Using**

<i>(In thousands)</i>	Total	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)	
U.S. Treasury obligations	\$ 9,988	\$	\$	9,988	\$	
GSE obligations	47,387			47,387		
Corporate debt securities	1,987			1,987		
Trust preferred CDOs	1,480					1,480
Collateralized mortgage obligations	60,750			60,750		
GSE mortgage-backed securities	204,814			204,814		
Total available for sale securities	326,406			324,926		1,480
Interest rate swap assets	482			482		
Interest rate swap liabilities	431			431		

A description of the valuation methodologies used for instruments measured at fair value, as well as the general classification of such instruments pursuant to the valuation hierarchy, is set forth below. These valuation

methodologies were applied to all of the Company's financial assets and financial liabilities carried at fair value effective January 1, 2008. In general, fair value is based upon quoted market prices, where available. If such quoted market prices are not available, fair value is based upon internally developed models that primarily use, as inputs, observable market-based parameters. Valuation adjustments may be made to ensure that financial instruments are recorded at fair value. These adjustments may include amounts to reflect counterparty credit quality and the Company's creditworthiness, among other things, as well as unobservable parameters. Any such valuation adjustments are applied consistently over time. The Company's valuation methodologies may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. While management believes the Company's valuation methodologies are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Table of Contents

Financial assets and financial liabilities measured at fair value on a recurring basis include the following:

Available for sale securities are reported at fair value primarily utilizing Level 2 inputs. The Company obtains fair value measurements from independent pricing sources, which base their fair value measurements upon observable inputs such as reported trades of comparable securities, broker quotes, the U.S. Treasury (the Treasury) yield curve, benchmark interest rates, market spread relationships, historic and consensus prepayment rates, credit information and the security's terms and conditions.

The Company used significant unobservable inputs (Level 3) to value two of its available for sale securities (CDO A and CDO B) at December 31, 2008. Each of these securities is a collateralized debt obligation backed by trust preferred securities. There is limited trading in these and comparable securities due to recent economic conditions and observable pricing has become more difficult to obtain. At December 31, 2008, the Company obtained valuations from four sources, including broker quotes and cash flow scenario analyses. The fair values obtained were assigned a weighting that was dependent upon the methods used to calculate the prices. Cash flow scenarios (Level 3) were given more weight than broker quotes (Level 2) because the broker quotes were believed to be based on distressed sales, evidenced by the inactive market. The weighting was then used to determine an overall fair value of the securities.

At September 30, 2009, management reviewed the fair values provided by the same pricing sources as used in the previous reporting periods. Based on management's understanding of the methods employed and the guidance provided by FSP No. FAS 157-4 (ASC 820-10-65), three of the four sources were excluded from the valuation process. These sources were excluded because either the assumptions used were inappropriate or because of the uncertainty surrounding the methodology in determining the fair values, including a previous source of cash flow scenario analyses that adopted the fair value methodology of a previously excluded source. As a result, broker quotes (Level 2) were used to determine the fair value of these securities. The broker quotes given for the securities were based on executed trades of similar collateral structure and performance. Although limited trades occurred, they were likely orderly transactions when considering the number of potential buyers the transactions were marketed to and the intention by the sellers to maximize their proceeds. The cash flow scenario analyses considered varying default, recovery and prepayment assumptions discounted at a rate representative of yields available for similar investments adjusted for credit risk. Management believes that the broker quotes are the best representation of the price that would be obtained for these particular securities in an orderly transaction under current market conditions.

The fair values for the interest rate swap assets and liabilities represent a Level 2 valuation and are based on settlement values adjusted for credit risks associated with the counterparties and the Company. Credit risk adjustments consider factors such as the likelihood of default by the Company and its counterparties, its net exposures and remaining contractual life. To date, the Company has not realized any losses due to a counterparty's inability to pay any net uncollateralized position. The change in value of interest rate swap assets and liabilities attributable to credit risk was not significant during the reported periods. See also *Note 6 Derivatives*.

Table of Contents

The following tables show a reconciliation of the beginning and ending balances for fair value measurements using significant unobservable inputs:

<i>(In thousands)</i>	Fair Value Measurements Using Significant Unobservable Inputs	
	2009	2008
	<i>Available for sale securities</i>	
Balance, January 1	\$ 1,480	\$ 974
Increase in unrealized holding losses	(299)	(538)
Other-than-temporary impairment	(696)	(219)
Transfers to Level 2	(485)	
Transfers to Level 3		1,642
Balance, September 30	\$	\$ 1,859

<i>(In thousands)</i>	Fair Value Measurements Using Significant Unobservable Inputs	
	2009	2008
	<i>Restructured Loans and Leases</i>	
Balance, January 1	\$	\$
Transfers to Level 3	996	
Balance, September 30	\$ 996	\$

Certain financial assets and financial liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis, but are subject to fair value adjustments in certain circumstances (for example, when there is evidence of impairment).

The following tables summarize the financial assets and financial liabilities measured at fair value on a nonrecurring basis as of and for the nine months ended September 30, 2009 and September 30, 2008, segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value:

<i>(In thousands)</i>	Total	Fair Value Measurements at September 30, 2009		
		Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Unobservable Inputs (Level 3)

Collateral-dependent loans and leases	\$	3,199	\$	\$	3,199	\$
Restructured loans		996				996
Other real estate owned		2,083			2,083	

**Fair Value Measurements at September 30, 2008
Using**

<i>(In thousands)</i>	Total	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Unobservable Inputs (Level 3)
Collateral-dependent loans and leases	\$ 3,308	\$	\$ 3,308	\$
Other real estate owned	352		352	

Table of Contents

Impaired loans and leases were \$8.1 million on September 30, 2009. Impaired loans and leases that are deemed collateral dependent are valued based upon the fair value of the underlying collateral. The inputs used in the appraisal of the collateral are observable and, therefore, categorized as Level 2. On September 30, 2009, the valuation allowance for collateral-dependent loans and leases was \$990,000. The valuation allowance increased by \$41,000 during the first nine months of 2009 from \$949,000 at December 31, 2008. Impaired loans that have been restructured are valued based on expected future cash flows. The expected future cash flows consider the agreed upon payment terms and various prepayment and default assumptions. These assumptions are not observable and are categorized as Level 3 inputs. On September 30, 2009, the valuation allowance for restructured loans was \$109,000. There were no restructured loans at December 31, 2008.

The aggregate fair value of financial assets and financial liabilities presented do not represent the underlying value of the Company taken as a whole. The fair value estimates provided are made at a specific point in time, based on relevant market information and the characteristics of the financial instrument. The estimates do not provide for any premiums or discounts that could result from concentrations of ownership of a financial instrument. Because no active market exists for some of the Company's financial instruments, certain fair value estimates are based on subjective judgments regarding current economic conditions, risk characteristics of the financial instruments, future expected loss experience, prepayment assumptions and other factors. The resulting estimates involve uncertainties and therefore cannot be determined with precision. Changes made to any of the underlying assumptions could significantly affect the estimates. The estimated fair value approximates carrying value for cash and cash equivalents, overnight investments and accrued interest receivable and payable. The methodologies for other financial assets and financial liabilities are discussed below:

Loans and leases receivable - Fair value estimates are based on loans and leases with similar financial characteristics. Loans and leases have been segregated by homogenous groups into residential mortgage, commercial, and consumer and other loans. Fair values are estimated by discounting contractual cash flows, adjusted for prepayment estimates, using discount rates approximately equal to current market rates on loans with similar characteristics and maturities. The incremental credit risk for nonperforming loans has been considered in the determination of the fair value of loans.

Stock in the Federal Home Loan Bank of Boston - The fair value of stock in the FHLB equals the carrying value reported in the balance sheet. This stock is redeemable at full par value only by the FHLB. The FHLB has suspended its quarterly dividend and has placed a moratorium on excess stock repurchases. On August 12, 2009, the FHLB filed its Form 10-Q, for the six months ended June 30, 2009, with the SEC. The FHLB reported a net loss of \$87.6 million for the first six months of 2009. Additionally, it reported a decrease in total capital of \$830.6 million and an increase in capital stock of \$30.7 million during the six months ended June 30, 2009. On October 29, 2009 the FHLB issued a letter to member banks detailing certain highlights from its third quarter of 2009 results. These financial highlights included a net loss of \$105.4 million for the quarterly period, while the total capital balance of \$2.6 billion remained consistent with that of the second quarter of 2009. Despite the negative trends, the FHLB continues to exceed the regulatory capital requirements promulgated by the Federal Home Loan Banks Act and the Federal Housing Financing Agency through September 30, 2009. The FHLB has the capacity to issue additional debt if necessary to raise cash. If needed, the FHLB also has the ability to secure funding available to GSE enterprises through the U.S. Treasury. Based on the capital adequacy and the liquidity position of the FHLB, management believes there is no impairment related to the carrying amount of the Company's FHLB stock as of September 30, 2009. Further deterioration of the FHLB's capital levels may require the Company to deem its restricted investment in FHLB stock to be other-than-temporarily impaired. If evidence of impairment exists in the future, the FHLB stock would reflect fair value using either observable or unobservable inputs.

Deposits - The fair values reported for demand deposit, NOW, money market, and savings accounts are equal to their respective book values reported on the balance sheet. The fair values disclosed are, by definition, equal to the amount payable on demand at the reporting date. The fair values reported for certificate of deposit accounts are based on the discounted value of contractual cash flows. The discount rates used are representative of approximate rates currently offered on certificate of deposit accounts with similar remaining maturities. The estimated fair value of deposits does not take into account the value of the Company's long-term relationships with depositors. Nonetheless, the Company

would likely realize a core deposit premium if its deposit portfolio was sold in the principal market for such deposits.

Table of Contents

Wholesale repurchase agreements - The fair values reported for wholesale repurchase agreements are based on the discounted value of contractual cash flows. The discount rates used are representative of approximate rates currently offered on borrowings with similar characteristics and maturities.

Federal Home Loan Bank of Boston borrowings - The fair values reported for FHLB borrowings are based on the discounted value of contractual cash flows. The discount rates used are representative of approximate rates currently offered on borrowings with similar characteristics and maturities.

Subordinated deferrable interest debentures - The fair values reported for subordinated deferrable interest debentures are based on the discounted value of contractual cash flows. The discount rates used are representative of approximate rates currently offered on instruments with similar terms and maturities.

Financial instruments with off-balance sheet risk - Since the Bank's commitments to originate or purchase loans, and for unused lines and outstanding letters of credit, are primarily at market interest rates, there is no significant fair value adjustment.

The book values and estimated fair values for the Company's financial instruments are as follows:

	September 30, 2009		December 31, 2008	
	Book Value	Estimated Fair Value	Book Value	Estimated Fair Value
	(In thousands)			
Assets:				
Cash and due from banks	\$ 19,020	\$ 19,020	\$ 54,344	\$ 54,344
Overnight investments	523	523	1,113	1,113
Available for sale securities	365,706	365,706	326,406	326,406
Stock in the FHLB	16,274	16,274	15,671	15,671
Loans and leases receivable, net of allowance for loan and lease losses:				
Commercial loans and leases	711,154	724,243	646,814	662,072
Residential mortgage loans	180,677	184,090	211,325	208,669
Consumer and other loans	208,259	207,509	204,939	199,252
Interest rate swaps	471	471	482	482
Accrued interest receivable	4,826	4,826	5,240	5,240
Liabilities:				
Deposits:				
Demand deposit accounts	\$ 206,534	\$ 206,534	\$ 176,495	\$ 176,495
NOW accounts	62,333	62,333	56,703	56,703
Money market accounts	50,380	50,380	4,445	4,445
Savings accounts	365,857	365,857	381,106	381,106
Certificate of deposit accounts	406,827	410,157	423,443	427,571
Overnight and short-term borrowings	39,031	39,031	57,676	57,676
Wholesale repurchase agreements	20,000	20,559	10,000	11,075
FHLB borrowings	267,647	294,137	238,936	266,723
Subordinated deferrable interest debentures	13,403	15,156	13,403	15,262
Interest rate swaps	477	477	431	431
Accrued interest payable	1,842	1,842	2,600	2,600

Table of Contents**(8) Contingent Liabilities**

In June 2009, the Bank received a Notice of Assessment from the Massachusetts Department of Revenue (DOR) challenging the 2002 to 2006 state income tax due from BRI Investment Corp., a Rhode Island passive investment company. The DOR seeks to collapse the income from BRI Investment Corp. into the Bank s income and assess state corporate excise tax on the resulting apportioned income. The tax assessment and accrued interest and penalties total approximately \$450,000. The passive investment company is not subject to corporate income tax in the State of Rhode Island. The Bank filed an Application for Abatement in September 2009 contesting the assessment and asserting its position. Management believes it more likely than not that the Bank will prevail in its tax position.

(9) U.S. Treasury s Capital Purchase Program

On August 5, 2009, the Company repurchased the U.S. Treasury Department s \$30.0 million preferred stock investment and exited the Treasury s Capital Purchase Program (CPP). The Company repurchased all 30,000 shares of Fixed Rate Cumulative Perpetual Preferred Stock, Series A, with a liquidation value of \$1,000 per share and paid accrued dividends through the date of repurchase of \$333,333. The repurchase of the preferred stock investment resulted in the recognition of \$1.3 million in prepayment charges on the discount associated with its issuance. As part of the CPP, the Company also issued the Treasury a warrant to purchase 192,967 shares of common stock with an initial exercise price of \$23.32 per share. On September 30, 2009, the Company repurchased the warrant for \$1.4 million.

While the Company was not required to raise additional capital in order to repay the CPP funds, the Company s Board of Directors (the Board) believed it was prudent to assure access to capital on reasonable terms should economic conditions deteriorate more than anticipated. Also, a commitment for additional capital would provide the Company with increased flexibility in responding to market developments.

As a result, the Company entered into a Standby Commitment Letter Agreement (the Commitment Agreement) on August 5, 2009 with a trust of which Malcolm G. Chace, the Company s Chairman of the Board and owner of more than 10% of the Company s outstanding common stock, is a trustee and beneficiary (the Purchaser). Pursuant to this commitment, the Company will have the right, exercisable at any time through February 5, 2011, to require the Purchaser to purchase up to \$8.0 million of trust preferred securities to be issued by a trust subsidiary of the Company (the Trust Subsidiary). At the time of the purchase of the trust preferred securities by the Purchaser, the Company would purchase all of the common securities of the Trust Subsidiary, in an amount equal to at least 3% of the total capital of the Trust Subsidiary. The Trust Subsidiary would in turn use the proceeds from the sale of the trust preferred and the common securities to acquire floating rate junior subordinated notes of the Company. Under the terms of the Commitment Agreement, the Purchaser deposited and must maintain at least \$9.2 million of cash and/or securities in a control account to secure the Purchaser s obligation to purchase the trust preferred securities at the option of the Company. If and when issued, the trust preferred securities will bear interest at a rate equal to the 3-Month LIBOR plus 7.98%, subject to a maximum annual rate of 14.00%. As consideration for the commitment, the Company paid a \$320,000 commitment fee to the Purchaser, representing 4% of the maximum commitment.

Table of Contents***ITEM 2. Management's Discussion and Analysis*****General**

The Company's principal subsidiary, Bank Rhode Island, is a commercial bank chartered as a financial institution in the State of Rhode Island. The Bank pursues a community banking mission and is principally engaged in providing banking products and services to businesses and individuals in Rhode Island and nearby areas of Massachusetts. The Bank offers its customers a wide range of business, commercial real estate, consumer and residential loans and leases, deposit products, nondeposit investment products, cash management, private banking and other banking products and services designed to meet the financial needs of individuals and small- to mid-sized businesses. The Bank also offers both commercial and consumer online banking products and maintains a web site at <http://www.bankri.com>. The Bank competes with a variety of traditional and nontraditional financial service providers both within and outside of Rhode Island. The Company and Bank are subject to the regulations of certain federal and state agencies and undergo periodic examinations by certain of those regulatory authorities. The Bank's deposits are insured by the FDIC, subject to regulatory limits. The Bank is also a member of the Federal Home Loan Bank of Boston (FHLB). The Company's common stock is traded on the Nasdaq Global Select MarketSM under the symbol BARI. The Company's financial reports can be accessed through its website within 24 hours of filing with the SEC.

Critical Accounting Policies

Accounting policies involving significant judgments and assumptions by management, which have, or could have, a material impact on the carrying value of certain assets or net income, are considered critical accounting policies. The preparation of financial statements in accordance with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities. Actual results could differ from those estimates. As discussed in the Company's 2008 Annual Report on Form 10-K, management has identified the accounting for the allowance for loan and lease losses, review of goodwill for impairment, valuation of available for sale securities and income taxes as the Company's most critical accounting policies.

As a result of the adoption of FSP No. FAS 115-2 and FAS 124-2 (ASC 320-10), effective April 1, 2009, the Company has revised its critical accounting policy pertaining to other-than-temporary impairment of available for sale securities. FSP No. FAS 115-2 and FAS 124-2 (ASC 320-10) applied to existing and new debt securities held by the Company as of April 1, 2009, the beginning of the interim period in which it was adopted. Therefore, the revised accounting policy below represents only the change in the Company's critical accounting policies from those disclosed in the Company's 2008 Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and applies prospectively beginning April 1, 2009.

Valuation of available for sale securities

Debt securities can be classified as trading, available for sale or held-to-maturity. Securities are classified as trading and carried at fair value, with unrealized gains and losses included in earnings, if they are bought and held principally for the purpose of selling in the near term. Debt securities are classified as held-to-maturity and carried at amortized cost only if the Company has the positive intent and ability to hold these securities to maturity. Securities not classified as either held-to-maturity or trading are classified as available for sale and reported at fair value, with unrealized gains and losses excluded from earnings and reported as a separate component of shareholders' equity, net of estimated income taxes. As of September 30, 2009 and December 31, 2008, all of the Company's investment securities were classified as available for sale.

The Company performs regular analysis on the available for sale securities portfolio to determine whether a decline in fair value indicates that an investment is other-than-temporarily impaired. Management considers various factors in making these determinations including the length of time and extent to which the fair value has been less than amortized cost, projected future cash flows, credit subordination and the creditworthiness, capital adequacy and near-term prospects of the issuers. Management also considers capital adequacy, interest rate risk, liquidity and business plans in assessing whether it is more likely than not that the Company will sell or be required to sell the securities before recovery.

Table of Contents

If the Company determines that a decline in fair value is other-than-temporary and that it is more likely than not that the Company will not sell or be required to sell the security before recovery of its amortized cost, the credit portion of the impairment loss is recognized in earnings and the noncredit portion is recognized in accumulated comprehensive income. The credit portion of the other-than-temporary impairment represents the difference between the amortized cost and the present value of the expected future cash flows of the security. If the Company determines that a decline in fair value is other-than-temporary and it will more likely than not sell or be required to sell the security before recovery of its amortized cost, the entire difference between the amortized cost and the fair value of the security will be recognized in earnings. Continued adverse economic and market conditions could result in losses from other-than-temporary impairment.

Overview

The primary drivers of the Company's operating income are net interest income, which is strongly affected by the net yield on interest-earning assets and liabilities (net interest margin), and the quality of the Company's assets.

The Company's net interest income represents the difference between interest income and its cost of funds. Interest income depends on the amount of interest-earning assets outstanding during the year and the interest rates earned thereon. Cost of funds is a function of the average amount of deposits and borrowed money outstanding during the year and the interest rates paid thereon. The net interest margin is calculated by dividing net interest income by average interest-earning assets. Net interest spread is the difference between the average rate earned on interest-earning assets and the average rate paid on interest-bearing liabilities. Net interest margin generally exceeds the net interest spread as a portion of interest-earning assets is funded by various noninterest-bearing sources (primarily noninterest-bearing deposits and shareholders' equity). The increases (decreases) in the components of interest income and interest expense, expressed in terms of fluctuation in average volume and rate, are summarized under *Rate/Volume Analysis* on page 39. Information as to the components of interest income and interest expense and average rates is provided under *Average Balances, Yields and Costs* on page 38.

Because the Company's assets are not identical in duration and in repricing dates to its liabilities, the spread between the two is vulnerable to changes in market interest rates as well as the overall shape of the yield curve. These vulnerabilities are inherent to the business of banking and are commonly referred to as interest rate risk. How to measure interest rate risk and, once measured, how much risk to take are based on numerous assumptions and other subjective judgments. See also discussion under *Interest Rate Risk* on page 48.

The quality of the Company's assets also influences its earnings. Loans and leases that are not paid on a timely basis and exhibit other weaknesses can result in the loss of principal and/or interest income. Additionally, the Company must make timely provisions to the allowance for loan and lease losses based on estimates of probable losses inherent in the loan and lease portfolio; these additions, which are charged against earnings, are necessarily greater when greater probable losses are expected. Further, the Company incurs expenses as a result of resolving troubled assets. All of these reflect the credit risk that the Company takes on in the ordinary course of business and are further discussed under *Financial Condition Asset Quality* on pages 32 to 34.

The Company's business strategy has been to concentrate its asset generation efforts on commercial and consumer loans and its deposit generation efforts on checking and savings accounts. These deposit accounts are commonly referred to as core deposits. This strategy is based on the Company's belief that it can distinguish itself from its larger competitors, and indeed attract customers from them, through a higher level of service and through its ability to set policies and procedures, as well as make decisions locally. The loan and deposit products referenced also tend to be geared more toward customers who are relationship oriented than those who are seeking stand-alone or single transaction products. The Company believes that its service-oriented approach enables it to compete successfully for relationship-oriented customers. Additionally, the Company is predominantly an urban franchise with a high concentration of businesses, which makes deployment of funds in the commercial lending area practicable. Commercial loans are attractive to the Company, among other reasons, because of their higher yields. Similarly, core deposits are attractive to the Company because of their generally lower interest cost and potential for fee income.

Table of Contents

The deposit market in Rhode Island is highly concentrated. The State's three largest banks have an aggregate market share of approximately 84% (based upon June 2009 FDIC statistics, excluding one bank that draws its deposits primarily from the internet) in Providence and Kent Counties, the Bank's primary marketplace. Competition for loans and deposits remains intense. This competition has resulted in considerable advertising and promotional product offerings by competitors, including print, radio and television media as well as web-based advertising and promotions. The Company also seeks to leverage business opportunities presented by its customer base, franchise footprint and resources. In 2005, the Bank completed the acquisition of an equipment leasing company located in Long Island, New York (Macrolease) and formed a private banking division. The Bank is using the Macrolease platform to increase the Bank's loan and lease portfolio, as well as to generate additional income by originating equipment leases for third parties.

For the nine months ended September 30, 2009, approximately 84% of the Company's revenues (defined as net interest income plus noninterest income) were derived from its net interest income. In a continuing effort to diversify its sources of revenue, the Company has sought to expand its sources of noninterest income (primarily fees and charges for products and services the Bank offers). Service charges on deposit accounts remain the largest component of noninterest income. The future operating results of the Company will depend upon on the ability to maintain its net interest margin, while minimizing its exposure to credit risk, along with increasing sources of noninterest income, while controlling the growth of noninterest or operating expenses.

Table of Contents**Financial Condition Executive Summary**

Selected balance sheet data is presented in the table below as of the dates indicated:

<i>(In thousands)</i>	September 30, 2009	June 30, 2009	March 31, 2009	December 31, 2008	September 30, 2008
Total assets	\$ 1,569,880	\$ 1,584,482	\$ 1,548,863	\$ 1,528,974	\$ 1,489,980
Loans and leases receivable	1,116,627	1,117,655	1,105,298	1,077,742	1,060,739
Available for sale securities	365,706	376,026	356,681	326,406	333,431
Goodwill	12,051	12,051	12,051	12,019	12,019
Core deposits ⁽¹⁾	685,104	681,834	636,240	618,749	615,085
Certificates of deposit	406,827	402,839	419,621	423,443	407,069
Borrowings	340,081	336,244	320,517	320,015	338,862
Common shareholders equity	122,476	120,471	122,306	121,010	114,226
Book value per common share	26.57	26.18	26.57	26.45	24.97
Tangible book value per common share	23.96	23.56	23.95	23.82	22.34
Tangible common equity ratio ^{(2) (3)}	7.09%	6.90%	7.17%	7.18%	6.92%
Core deposits to total deposits ^{(1) (3)}	62.7%	62.9%	60.3%	59.4%	60.2%

(1) Core deposits consist of demand deposit, NOW, money market and savings accounts.

(2) Calculated by dividing Common Shareholders Equity less Goodwill by Total Assets less Goodwill.

(3) Non-GAAP performance measure.

Total assets increased by \$40.9 million since December 31, 2008. Total loans and leases increased by \$38.9 million during the first nine months of 2009, with increases in commercial loans and leases of \$66.0 million, or 10.0%, and consumer and other loans of \$3.2 million, or 1.6%, respectively. The residential mortgage loan portfolio decreased by \$30.4 million, or 14.3%. Available for sale securities increased \$39.3 million, or 12.0%, since year-end. The Bank's

core deposits increased by \$66.4 million, or 10.7%, since year-end. Within this increase, demand deposit accounts increased by \$30.0 million, or 17.0%, money market accounts increased by \$45.9 million, or 1033.4%, due to a new product offering, NOW accounts increased by \$5.6 million, or 9.9%, and savings accounts decreased by \$15.2 million, or 4.0%. Certificate of deposit accounts decreased by \$16.6 million, or 3.9%, and borrowings increased by \$20.1 million, or 6.3%, since year-end. Shareholders' equity as a percentage of total assets was 7.8% at September 30, 2009 and 9.8% at December 31, 2008.

The Company's financial position at September 30, 2009 as compared to September 30, 2008 reflects net growth of \$55.9 million in total loans and leases. This increase reflects the continuing conversion of the balance sheet to a more commercial profile with increases in commercial loans and leases of \$84.8 million, or 13.3%. Consumer loans increased \$3.9 million, or 1.9%, from the prior year quarter-end. The residential mortgage portfolio declined \$32.8 million, or 15.3%, from September 30, 2008. Also, available for sale securities at September 30, 2009 increased by \$32.3 million, or 9.7%, from the same period in 2008. Core deposits have increased \$70.0 million, or 11.4%, since the prior year quarter-end, with growth centered in money market accounts of \$46.4 million, demand deposit accounts of \$25.2 million and NOW accounts of \$6.1 million. These increases were offset by a decrease in savings accounts of \$7.7 million and certificate of deposit accounts of \$242,000 since September 30, 2008. Borrowings have increased by \$1.2 million from the same period in 2008.

Table of Contents**Financial Condition Detailed Analysis****Investments**

Total investments consist of available for sale securities, stock in the FHLB and overnight investments. Total investments comprised \$382.5 million, or 24.4% of total assets at September 30, 2009, compared to \$343.2 million, or 22.4% of total assets at December 31, 2008, representing an increase of \$39.3 million, or 11.5%. Available for sale securities are recorded at fair value. At September 30, 2009, the fair value of available for sale securities was \$365.7 million and carried a total of \$4.5 million of net unrealized gain at the end of the quarter, compared to \$639,000 at December 31, 2008.

The investment portfolio provides the Company a source of short-term liquidity and acts as a counterbalance to loan and deposit flows. During the first nine months of 2009, the Company purchased \$163.6 million of available for sale securities compared to \$116.9 million during the same period in 2008. Maturities, calls and principal repayments totaled \$126.5 million for the nine months ended September 30, 2009 compared to \$91.1 million for the same period in 2008. Additionally, in the first nine months of 2009, the Company sold \$1.9 million of available for sale securities generating gains of \$61,000 compared to sales of \$22.5 million and gains of \$410,000 for the same period in 2008.

The Company performs regular analysis on the available for sale securities portfolio to determine whether a decline in fair value indicates that an investment is other-than-temporarily impaired. In making these other-than-temporary determinations, management considers, among other factors, the length of time and extent to which the fair value has been less than amortized cost, projected future cash flows, credit subordination and the creditworthiness, capital adequacy and near-term prospects of the issuers. Management also considers the Company's capital adequacy, interest rate risk, liquidity and business plans in assessing whether it is more likely than not that the Company will sell or be required to sell the securities before recovery.

If the Company determines that a decline in fair value is other-than-temporary and that it is more likely than not that the Company will not sell or be required to sell the security before recovery of its amortized cost, the credit portion of the impairment loss is recognized in earnings and the noncredit portion is recognized in accumulated comprehensive income. The credit portion of the other-than-temporary impairment represents the difference between the amortized cost and the present value of the expected future cash flows of the security. If the Company determines that a decline in fair value is other-than-temporary and it will more likely than not sell or be required to sell the security before recovery of its amortized cost, the entire difference between the amortized cost and the fair value of the security will be recognized in earnings.

In performing the analysis for the two collateralized debt obligations (CDO A and CDO B) held by the Company, which are backed by pools of trust preferred securities, future cash flow scenarios for each security were estimated based on varying levels of severity for assumptions of future delinquencies, recoveries and prepayments. These estimated cash flow scenarios were used to determine whether the Company expects to recover the amortized cost basis of the securities. Projected credit losses were compared to the current level of credit enhancement to assess whether the security is expected to incur losses in any future period and therefore become other-than-temporarily impaired.

Upon adoption of FSP No. FAS 115-2 and FAS 124-2 (ASC 320-10) in the second quarter of 2009, management reevaluated the other-than-temporary impairment that was previously recognized on CDO A at September 30, 2008. Management determined that it did not meet the criteria for other-than-temporary impairment as defined by FSP No. FAS 115-2 and FAS 124-2 (ASC 320-10) because the amortized cost basis of the security was expected to be recovered, management had no intent to sell the security before recovery and it was more likely than not that the Company would not be required to sell the security before recovery. As a result, an adjustment of \$137,000, representing the previously recognized other-than-temporary impairment charge, net of accretion recognized on impairment and tax effects, has been applied to the opening balance of retained earnings with a corresponding adjustment to accumulated other comprehensive income.

Table of Contents

During September 2009, CDO A experienced an additional \$10.0 million in defaulting collateral. Projected credit loss severity assumptions were increased in estimated future cash flow scenarios and it was determined that management does not expect to recover \$70,000 of the security's amortized cost. As a result, the Company recorded an other-than-temporary impairment totaling \$696,000, representing the difference between the security's fair value and book value. The portion deemed to be credit related of \$70,000 has been recorded as a reduction to noninterest income, while the non-credit portion of \$626,000 has been recorded as a reduction of other comprehensive income. Management will continue to monitor this security for further potential impairment.

Management reviewed CDO B and assessed the issuer's ability to continue to make principal and interest payments. The Company did not receive its September interest payment because the security is adding interest to the principal rather than paying out. However, management reviewed various cash flow scenarios driven by varying assumptions (including default rates and recoveries) for this instrument and determined that although current and future deferrals and defaults may cause a temporary break in interest payments, management expects to recover the amortized cost of the security due to the structure of the instrument. The structure is such that payments to all junior subordinated tranches of the instrument (of which there are two) are diverted to senior level tranches until they meet certain over-collateralization tests. Essentially, the senior level tranches will continue to be paid until there are no further funds available from the junior tranches. Because management expects to recover the amortized cost of the security and it is more likely than not that the security will not be sold, no other-than-temporary impairment exists at September 30, 2009.

The decline in fair value of the remaining available for sale securities in an unrealized loss position is due to a substantial widening of interest rate spreads across market sectors related to the continued illiquidity and uncertainty of the securities markets. Management believes that it will recover the amortized cost basis of the securities and that it is more likely than not that it will not be required to sell the securities before recovery. Additionally, management has no intent to sell the securities before recovery. As such, management has determined that the securities are not other-than-temporarily impaired as of September 30, 2009. If market conditions for securities worsen or the creditworthiness of the underlying issuers deteriorates, it is possible that the Company may recognize additional other-than-temporary impairments in future periods.

As of September 30, 2009, the Company's remaining securities in an unrealized loss position were deemed not to be other-than-temporarily impaired after considering the aforementioned factors. The Company does not have the intent to sell the securities with unrealized losses until recovery or maturity and believes it is more likely than not that it will not be required to sell the securities before recovery and that it will recover the amortized cost basis of the securities.

Loans and Leases

Total loans and leases increased by \$38.9 million since December 31, 2008 and stood at \$1.12 billion at September 30, 2009. As a percentage of total assets, loans and leases increased to 71.1% at September 30, 2009, compared to 70.5% at December 31, 2008. This increase was centered in commercial loans, where the Company concentrates its origination efforts, and was partially offset by decreases in residential mortgage loans, which the Company has historically purchased. Total loans and leases as of September 30, 2009 are comprised of three broad categories: commercial loans and leases that aggregate \$724.4 million, or 64.9% of the portfolio; residential mortgages that aggregate \$182.3 million, or 16.3% of the portfolio; and consumer and other loans that aggregate \$209.9 million, or 18.8% of the portfolio.

Commercial loans and leases The commercial loan and lease portfolio (consisting of commercial real estate, commercial and industrial, equipment leases, multi-family real estate, construction and small business loans) increased \$66.0 million, or 10.0%, during the first nine months of 2009. The primary drivers of this growth occurred in the commercial real estate, commercial and industrial and leasing areas.

The Bank's business lending group originates business loans, also referred to as commercial and industrial loans. In addition, Macrolase-generated equipment loans are included in the commercial and industrial loan portfolio. Total commercial and industrial loans increased \$19.3 million, or 11.8%, since year-end.

Table of Contents

The Bank's business lending group also originates owner-occupied commercial real estate loans, term loans and revolving lines of credit. Since December 31, 2008, owner-occupied commercial real estate loans decreased by \$8.3 million, or 4.7%.

The Bank's commercial real estate (CRE) group originates nonowner-occupied commercial real estate, multi-family residential real estate and construction loans. These real estate secured commercial loans are offered as both fixed and adjustable-rate products. Since December 31, 2008, CRE loans have increased \$36.8 million, or 17.6%, on a net basis. The Bank purchases equipment leases from originators outside of the Bank. The U.S. Government or its agencies are the principal lessees on these purchased leases. These government leases generally have maturities of five years or less and are not dependent on residual collateral values. At September 30, 2009, \$7.4 million of purchased government leases were included in the commercial loan and lease portfolio representing a decrease of \$1.2 million, or 14.4%, since year-end.

With the Macrolease platform, the Bank originates and purchases equipment loans and leases for its own portfolio, as well as originates loans and leases for third parties as a source of noninterest income. Macrolease-generated equipment loans of \$43.0 million and \$35.2 million were included in the commercial and industrial portfolio at September 30, 2009 and December 31, 2008, respectively. Since December 31, 2008, total Macrolease-generated equipment loans and leases increased \$22.7 million, or 26.5%, to \$108.4 million.

At September 30, 2009, small business loans (business lending relationships of approximately \$500,000 or less) were \$55.4 million, or 7.7% of the portfolio, compared to \$50.5 million, or 7.7% of the portfolio, at December 31, 2008. These loans reflect those originated by the Bank's business development group, as well as throughout the Bank's branch system. The Bank utilizes credit scoring and streamlined documentation, as well as traditional review standards in originating these credits.

The Bank is a participant in the U.S. Small Business Administration (SBA) Lender Program in both Rhode Island and Massachusetts. The Bank was named the No. 1 SBA lender in Rhode Island as of the SBA's fiscal year end at September 30, 2009. SBA guaranteed loans exist throughout the portfolios managed by the Bank's various lending groups.

The Company believes it is well positioned for continued commercial growth. The Bank places particular emphasis on the generation of small- to medium-sized commercial relationships (those with \$10.0 million or less in total loan commitments).

Residential mortgage loans Since inception, the Bank has concentrated its portfolio lending efforts on commercial and consumer lending opportunities, but originates mortgage loans for its own portfolio on a limited basis. During 2009, the Bank added two mortgage originators to improve business generation, increasing the department to a team of three. Historically, the Bank has purchased residential mortgage loans from third-party originators. During the nine months ended 2009, residential mortgage loans decreased \$30.4 million, or 14.3%. During this period, the Bank originated \$2.7 million of mortgages for the portfolio. Comparatively, during the first nine months of 2008, the Bank originated \$2.1 million of mortgages for the portfolio. No mortgages were purchased for the portfolio during the first nine months of 2009 or 2008. The Bank may purchase residential mortgage loans with high credit quality to utilize available cash flow if and when opportunities arise.

Consumer loans The consumer loan portfolio increased \$3.2 million, or 1.6%, during the first nine months of 2009 as originations and advances of \$38.4 million exceeded repayments of \$34.9 million. The increase in growth through September 30, 2009 was reflective of the Company's home equity loan promotions during the first nine months of the year. The Company continues to offer consumer lending as it believes that these amortizing fixed rate products, along with floating rate lines of credit, possess attractive cash flow characteristics.

Table of Contents

The following is a summary of loans and leases receivable:

	September 30, 2009	December 31, 2008
	<i>(In thousands)</i>	
Commercial loans and leases:		
Commercial real estate owner occupied	\$ 167,222	\$ 175,472
Commercial and industrial	183,911	164,569
Commercial real estate nonowner occupied	163,766	133,782
Small business	55,442	50,464
Multi-family	58,622	53,159
Construction	23,630	22,300
Leases and other ^(a)	78,506	63,799
Subtotal	731,099	663,545
Unearned lease income	(9,218)	(6,980)
Net deferred loan origination costs	2,540	1,857
Total commercial loans and leases	724,421	658,422
Residential mortgage loans:		
One- to four-family adjustable rate	112,098	126,689
One- to four-family fixed rate	69,702	85,057
Subtotal	181,800	211,746
Premium on loans acquired	528	953
Net deferred loan origination fees	(25)	(34)
Total residential mortgage loans	182,303	212,665
Consumer loans:		
Home equity term loans	123,662	127,142
Home equity lines of credit	83,404	76,038
Unsecured and other	1,743	2,216
Subtotal	208,809	205,396
Net deferred loan origination costs	1,094	1,259
Total consumer loans	209,903	206,655
Total loans and leases receivable	\$ 1,116,627	\$ 1,077,742

(a) Included within
commercial
loans and leases

were leases held for sale of \$156,000 at December 31, 2008. There were no leases held for sale at September 30, 2009.

Deposits

Total deposits increased by \$49.7 million, or 4.8%, during the first nine months of 2009, from \$1.04 billion, or 68.2% of total assets at December 31, 2008 to \$1.09 billion, or 69.6% of total assets at September 30, 2009.

The following table sets forth certain information regarding deposits:

	September 30, 2009			December 31, 2008		
	Amount	Percent Of Total	Weighted Average Rate	Amount	Percent of Total	Weighted Average Rate
			<i>(In thousands)</i>			
NOW accounts	\$ 62,333	5.7%	0.08%	\$ 56,703	5.5%	0.10%
Money market accounts	50,380	4.6%	1.26%	4,445	0.4%	0.39%
Savings accounts	365,857	33.5%	0.77%	381,106	36.6%	1.46%
Certificate of deposit accounts	406,827	37.3%	2.12%	423,443	40.6%	3.29%
Total interest bearing deposits	885,397	81.1%	1.37%	865,697	83.1%	2.26%
Noninterest bearing accounts	206,534	18.9%	0.00%	176,495	16.9%	0.00%
Total deposits	\$ 1,091,931	100.0%	1.11%	\$ 1,042,192	100.0%	1.89%

Table of Contents

During the first nine months of 2009, competition for deposits remained strong in the Company's market areas. Money market accounts and demand deposit accounts grew \$45.9 million and \$30.0 million, respectively, over the past nine months. NOW accounts grew to \$62.3 million, an increase of \$5.6 million from \$56.7 million at December 31, 2008. These increases offset the decline in certificate of deposit accounts (CDs) of \$16.6 million and savings accounts of \$15.2 million. At September 30, 2009, brokered CDs were \$28.5 million, or 2.6% of total deposits, compared to \$30.0 million, or 2.9% at year-end. The Bank may continue to utilize brokered CDs if rates are attractive compared to wholesale funding.

Borrowings

On a long-term basis, the Company intends to continue concentrating on increasing its core deposits and may utilize FHLB borrowings, brokered deposits or repurchase agreements as cash flows dictate, as opportunities present themselves and as part of the Bank's overall strategy to manage interest rate risk. The Bank also may borrow from the Federal Reserve discount window on occasion to support its liquidity.

The Bank routinely enters into repurchase agreements with its larger deposit and commercial customers as part of its cash management services. These repurchase agreements represent an additional source of funds and are typically overnight borrowings. The Bank also borrows funds through the use of wholesale repurchase agreements with correspondent banks. Overnight and short-term borrowings decreased \$18.6 million during the first nine months of 2009 from the December 31, 2008 level of \$57.7 million. FHLB borrowings increased by \$28.7 million from the December 31, 2008 amount of \$238.9 million. Wholesale repurchase agreements increased by \$10.0 million from the December 31, 2008 balance of \$10.0 million. The Bank may utilize wholesale repurchase agreement funding or brokered CDs in the future if spreads are favorable compared to FHLB borrowings.

Asset Quality

Nonperforming assets consist of nonperforming loans and other real estate owned (OREO). Nonperforming loans nonaccrual loans, loans past due 90 days or more, but still accruing and impaired loans. Under certain circumstances the Company may restructure the terms of a loan as a concession to a borrower. These restructured loans are generally considered nonperforming loans until a history of collection on the restructured terms of the loan has been established. OREO consists of real estate acquired through foreclosure proceedings and real estate acquired through acceptance of a deed in lieu of foreclosure.

Nonperforming assets At September 30, 2009, the Company had nonperforming assets of \$16.9 million, representing 1.08% of total assets compared to nonperforming assets of \$15.2 million, or 1.00% of total assets at December 31, 2008.

The following table sets forth information regarding nonperforming assets and loans and leases 60-89 days past due as of the dates indicated:

	September 30, 2009	December 31, 2008
	<i>(In thousands)</i>	
Loans and leases accounted for on a nonaccrual basis	\$ 13,965	\$ 14,045
Loans and leases past due 90 days or more, but still accruing	275	324
Restructured loans and leases on a nonaccrual basis	659	
Total nonperforming loans and leases	14,899	14,369
Other real estate owned	1,995	863
Total nonperforming assets	\$ 16,894	\$ 15,232
Delinquent loans and leases 60-89 days past due	\$ 1,384	\$ 3,782

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form DEF 14A

Restructured loans and leases not included in nonperforming assets	\$	446	\$	32
Nonperforming loans and leases as a percent of total loans and leases		1.33%		1.33%
Nonperforming assets as a percent of total assets		1.08%		1.00%
Delinquent loans and leases 60-89 days past due as a percent of total loans and leases		0.12%		0.35%

Table of Contents

Included in nonaccrual loans and leases at September 30, 2009 were \$8.1 million of impaired loans and leases, with specific impairment reserves against these loans of \$1.1 million. At December 31, 2008, there were \$10.3 million of impaired loans and leases with specific impairment reserves of \$949,000.

The following table provides further detailed information regarding the types of nonperforming loans and leases as of the dates indicated:

	September 30, 2009	December 31, 2008
	<i>(Dollars in thousands)</i>	
Commercial Real Estate Nonperforming Loans	\$ 3,159	\$ 4,884
Commercial and Industrial Nonperforming Loans	3,263	2,802
Small Business Nonperforming Loans	585	892
Multifamily Nonperforming Loans	205	
Construction Nonperforming Loans	469	1,000
Nonperforming Leases	1,059	428
Residential Nonperforming Loans	5,175	4,314
Consumer Nonperforming Loans	984	49
 Total Nonperforming Loans and Leases	 \$ 14,899	 \$ 14,369

The Company evaluates the underlying collateral of each nonperforming loan and continues to pursue the collection of interest and principal. Management believes that the current level of nonperforming assets remains low relative to the size of the Company's loan portfolio and as compared to peer institutions. The weak economy has resulted in an increase in charge-offs and nonperforming assets in the first nine months of 2009 compared to years past. If current economic conditions continue or worsen, management believes it is likely that the level of nonperforming assets would increase, as would the level of charged-off loans.

Higher-Risk Loans - Certain types of loans, such as option ARM products, junior lien loans, high loan-to-value ratio loans, interest only loans, subprime loans and loans with initial teaser rates, can have a greater risk of non-collection than other loans. Additional information about higher-risk loans may be useful in understanding the risks associated with the loan portfolio and in evaluating any known trends or uncertainties that could have a material impact on the results of operations. As of September 30, 2009 and December 31, 2008, the Company had \$115.3 million and \$132.3 million, respectively, of junior lien home equity loans and lines of credit. The allowance for loan and lease losses attributable to these loans at September 30, 2009 and December 31, 2008 were \$1.1 million and \$1.2 million. Other types of higher-risk loans are either not material to the Company's consolidated financial statements or do not exist in the Company's portfolio.

Adversely classified assets - The Company's management classifies certain assets as substandard, doubtful or loss based on criteria established under banking regulations. An asset is considered substandard if inadequately protected by the current net worth and paying capacity of the obligor or of the collateral pledged, if any. Substandard assets include those characterized by the distinct possibility that the insured institution will sustain some loss if existing deficiencies are not corrected. Assets classified as doubtful have all of the weaknesses inherent in those classified substandard with the added characteristic that the weaknesses present make collection or liquidation in full, on the basis of currently existing facts, conditions and values, highly questionable and improbable. Assets classified as loss are those considered uncollectible and of such little value that their continuance as assets without the establishment of a specific loss reserve is not warranted.

At September 30, 2009, the Company had \$23.3 million of assets that were classified as substandard. This compares to \$22.7 million of assets that were classified as substandard at December 31, 2008. The Company had no assets that were classified as loss or doubtful at either date. Performing loans may or may not be adversely classified depending

upon management's judgment with respect to each individual loan. At September 30, 2009, included in the assets that were classified as substandard were \$8.4 million of performing loans. This compares to \$8.3 million of adversely classified performing loans as of December 31, 2008. These amounts constitute assets that, in the opinion of management, could potentially migrate to nonperforming or doubtful status. If current weak economic conditions continue or worsen, management believes it is likely that the level of adversely classified assets would increase. This in turn may necessitate further increases to the provision for loan losses in future periods.

Table of Contents***Allowance for Loan and Lease Losses***

During the first nine months of 2009, the Company made additions to the allowance for loan and lease losses of \$6.1 million and experienced net charge-offs of \$4.2 million compared to additions to the allowance for loan and lease losses of \$2.8 million and net charge-offs of \$1.2 million for the first nine months of 2008. The net charge-offs were primarily within the commercial loans and leases and residential mortgage portfolios. At September 30, 2009, the allowance for loan and lease losses stood at \$16.5 million and represented 110.9% of nonperforming loans and leases and 1.48% of total loans and leases outstanding. This compares to an allowance for loan and lease losses of \$14.7 million, representing 102.05% of nonperforming loans and 1.36% of total loans and leases outstanding at December 31, 2008.

An analysis of the activity in the allowance for loan and lease losses is as follows:

	Nine Months Ended September 30, 2009	Nine Months Ended September 30, 2008
	<i>(In thousands)</i>	
Balance at beginning of period	\$ 14,664	\$ 12,619
Loans and leases charged-off:		
Commercial real estate loans	(50)	(174)
Commercial and industrial loans	(1,770)	
Small business loans	(864)	(100)
Leases	(67)	(29)
Residential mortgage loans	(1,486)	(908)
Consumer and other loans	(59)	(67)
Total loans charged-off	(4,296)	(1,278)
Recoveries of loans and leases previously charged-off:		
Commercial and industrial loans	13	31
Small business loans	11	20
Leases	4	16
Residential mortgage loans	2	
Consumer and other loans	29	21
Table of Contents		76

Total recoveries of loans previously charged-off	59	88
Net charge-offs	(4,237)	(1,190)
Provision for loan and lease losses charged against income	6,110	2,770
Balance at end of period	\$ 16,537	\$ 14,199

Table of Contents

The following table represents the allocation of the allowance for loan and lease losses as of the dates indicated:

	September 30, 2009	December 31, 2008
	<i>(In thousands)</i>	
Loan category		
Commercial loans and leases	\$ 12,245	\$ 10,708
Residential mortgage loans	1,501	1,239
Consumer and other loans	1,516	1,609
Unallocated	1,275	1,108
Total	\$ 16,537	\$ 14,664

Assessing the appropriateness of the allowance for loan and lease losses involves substantial uncertainties and is based upon management's evaluation of the amounts required to meet estimated charge-offs in the loan and lease portfolio after weighing various factors. Management's methodology to estimate loss exposure includes an analysis of individual loans and leases deemed to be impaired, reserve allocations for various loan types based on payment status or loss experience and an unallocated allowance that is maintained based on management's assessment of many factors including the growth, composition and quality of the loan portfolio, historical loss experiences, general economic conditions and other pertinent factors. These risk factors are reviewed and revised by management where conditions indicate that the estimates initially applied are different from actual results. If credit performance is worse than anticipated, the Company could incur additional loan and lease losses in future periods. The unallocated allowance for loan and lease losses was \$1.3 million at September 30, 2009 compared to \$1.1 million at December 31, 2008. Management believes that the allowance for loan and lease losses, as of September 30, 2009, is appropriate.

While management evaluates currently available information in establishing the allowance for loan and lease losses, future adjustments to the allowance for loan and lease losses may be necessary if conditions differ substantially from the assumptions used in making the evaluations. Management performs a comprehensive review of the allowance for loan and lease losses on a quarterly basis. In addition, various regulatory agencies, as an integral part of their examination process, periodically review a financial institution's allowance for loan and lease losses and carrying amounts of other real estate owned. Such agencies may require the financial institution to recognize additions to the allowance based on their judgments about information available to them at the time of their examination.

Table of Contents**Results of Operations Executive Overview**

Selected income statement, per share data and operating ratios are presented in the table below for the three-month periods indicated:

<i>(In thousands, except per share data)</i>	For the three-month periods ended				
	September 30, 2009	June 30, 2009	March 31, 2009	December 31, 2008	September 30, 2008
Income statement data:					
Net interest income	\$ 12,666	\$ 11,573	\$ 11,082	\$ 11,715	\$ 11,921
Noninterest income	2,241	2,214	2,357	2,881	2,333
Noninterest expense	9,812	10,145	9,623	9,510	9,304
Net income	2,203	740	1,463	2,253	2,324
Net income applicable to common shares	779	303	1,027	2,195	2,324
Per share data:					
Diluted earnings per share	\$ 0.17	\$ 0.07	\$ 0.22	\$ 0.48	\$ 0.50
Dividends per common share	\$ 0.17	\$ 0.17	\$ 0.17	\$ 0.17	\$ 0.17
Operating ratios:					
Net interest margin ^{(1) (5)}	3.38%	3.10%	3.08%	3.29%	3.34%
Return on assets ^{(2) (5)}	0.56%	0.19%	0.39%	0.59%	0.62%
Return on equity ^{(3) (5)}	2.54%	1.00%	4.88%	5.09%	8.20%
Efficiency ratio ^{(4) (5)}	65.82%	73.58%	71.60%	65.15%	65.27%

(1) Calculated by dividing annualized Net Interest Income by Average Interest-Earning Assets.

(2) Calculated by dividing annualized Net Income by Average Total Assets.

(3) Calculated by dividing annualized Net Income Applicable to Common Shares by Average

Common
Shareholders
Equity.

(4) Calculated by
dividing
Noninterest
Expense by Net
Interest Income
plus Noninterest
Income.

(5) Non-GAAP
performance
measure.

The Company's 2009 third quarter net income of \$2.2 million increased by \$1.5 million, or 197.7%, from the prior quarter (three months ended June 30, 2009). Net income was down \$121,000, or 5.2%, on a comparative quarter basis (as compared to the three months ended September 30, 2008). Diluted earnings per common share (EPS) were up 142.9% on a linked-quarter basis (as compared to the three months ended June 30, 2009) and decreased 66.0% as compared to the same quarter a year ago.

The third quarter 2009 net interest income increased by \$1.1 million, or 9.4%, as compared to the second quarter of 2009. The increase in the net interest margin of 28 basis points (bps), to 3.38%, was due to the lower cost of liabilities of 34 bps and the increase in the yield on earning assets of 3 bps.

Compared to the third quarter of 2008, net interest income increased by \$745,000, or 6.2%, with a decrease in the yield on earning assets of 58 bps exceeded by decreases in the cost of funds of 71 bps. The Bank did not receive FHLB dividends during the third quarter of 2009, compared to \$119,000 during the same period in the prior year.

The provision for loan and lease losses of \$1.9 million for the three months ended September 30, 2009 decreased by \$700,000, or 26.9%, on a linked-quarter basis. In comparison to the third quarter of 2008, the provision for loan and lease losses increased by \$385,000, or 25.4%, from \$1.5 million. The Bank made additions to the allowance for loan and lease losses during the third quarter of 2009 in response to increased nonperforming and classified loans, higher charge-offs compared to the prior year third quarter, growth in the commercial loan portfolio and general economic conditions.

Table of Contents

Noninterest income for the third quarter of 2009 increased on a linked-quarter basis by \$27,000. Commissions on nondeposit investment products increased by \$211,000 and deposit service charges increased \$29,000 during the third quarter of 2009 while loan related fees declined by \$154,000 largely due to credit valuation adjustments of interest rate swap assets and liabilities. In addition, a loss of \$70,000 reduced noninterest income as a result of an available for sale security deemed other-than-temporarily impaired.

In comparison to the 2008 third quarter, noninterest income was down \$92,000. The third quarter of 2008 benefited from gains on the sale of available for sale securities of \$168,000, while no securities were sold during the third quarter of 2009. Service charges on deposit accounts declined \$73,000, loan related fees declined \$61,000, net gains on lease sales and commissions on loans declined \$42,000 and other miscellaneous income declined \$92,000. These declines were offset by lower impairment of available for sale securities of \$149,000, increases in commissions on nondeposit investment products of \$148,000 and increased income from bank-owned life insurance of \$47,000.

Noninterest expenses decreased on a linked-quarter basis by \$333,000, or 3.3%, with a decrease in FDIC insurance of \$674,000 primarily due to the special assessment imposed by the FDIC on financial institutions during the second quarter of 2009 and a decrease in professional services of \$37,000. Increases in salaries and employee benefits of \$298,000, loan workout and other real estate owned costs of \$70,000 and occupancy expense of \$32,000 partially offset the decreases.

Third quarter 2009 noninterest expenses increased \$508,000, or 5.5%, compared to the third quarter of 2008. FDIC insurance costs increased \$286,000 due to an increase in assessment rates for 2009. Salaries and benefits increased \$157,000, or 3.1%, loan workout and other real estate owned costs increased \$141,000, or 180.8%, and other miscellaneous expenses increased \$155,000, or 18.2%, compared to the third quarter a year ago. Within the net increase in noninterest expenses were decreases in professional services costs of \$100,000, or 14.1%, marketing of \$40,000, or 10.9%, data processing of \$38,000, or 5.5%, and occupancy of \$35,000, or 3.9%.

The Company's key operating ratios are return on assets, return on equity and the efficiency ratio. For the third quarter of 2009, each of these metrics improved compared to the prior quarter. Compared to the same quarter of the prior year, return on assets declined 6 bps and the efficiency ratio declined 55 bps. The decline of return on equity of 566 bps was largely due to the preferred stock dividends and discount associated with the Company's participation in the U.S. Treasury's Capital Purchase Program. The Company continues to focus on growing revenue while controlling the increase in expenses as part of its effort to improve earnings and build shareholder value.

Results of Operations – Comparison of the Three Months Ended September 30, 2009 and 2008**Net Interest Income**

Net interest income for the quarter ended September 30, 2009 was up \$745,000, or 6.2%, from the \$11.9 million earned in the third quarter of 2008. Net interest margin for the third quarter of 2009 of 3.38% increased from the net interest margin for the 2008 period of 3.34%. Average earning assets were up \$71.0 million, or 5.0%, and average interest-bearing liabilities were up \$38.0 million, or 3.2%, from the comparable period a year earlier.

Table of Contents

Average Balances, Yields and Costs - The following table sets forth certain information relating to the Company's average balance sheet and reflects the average yield on assets and average cost of liabilities for the three month periods indicated. Such yields and costs are derived by dividing income or expense by the average balance of assets or liabilities. Average balances are derived from daily balances and include nonperforming loans. Available for sale securities are stated at amortized cost.

<i>(In thousands)</i>	For the three months ended September 30,					
	Average Balance	Interest Earned/ Paid	Average Yield	Average Balance	Interest Earned/ Paid	Average Yield
Assets						
Earning assets:						
Overnight investments	\$ 851	\$ 1	0.06%	\$ 1,005	\$ 6	2.13%
Available for sale securities	360,586	3,876	4.26%	346,930	4,261	4.89%
Stock in the FHLB	16,024		0.00%	15,671	119	3.02%
Loans and leases receivable:						
Commercial loans and leases	718,175	10,437	5.78%	634,541	10,076	6.32%
Residential mortgage loans	187,041	2,302	4.92%	219,265	2,899	5.29%
Consumer and other loans	212,109	2,384	4.46%	206,381	2,776	5.35%
Total earning assets	1,494,786	19,000	5.06%	1,423,793	20,137	5.64%
Cash and due from banks	16,828			20,813		
Allowance for loan and lease losses	(17,088)			(13,456)		
Premises and equipment	12,604			13,057		
Goodwill, net	12,051			12,019		
Accrued interest receivable	4,355			4,965		
Bank-owned life insurance	29,465			24,794		
Prepaid expenses and other assets	9,865			8,907		
Total assets	\$ 1,562,866			\$ 1,494,892		
Liabilities and Shareholders						
Equity						
Interest-bearing liabilities:						
Deposits:						
NOW accounts	\$ 65,365	\$ 13	0.08%	\$ 60,800	\$ 33	0.22%
Money market accounts	43,543	140	1.27%	5,400	17	1.22%
Savings accounts	369,019	707	0.76%	383,211	1,510	1.57%
Certificate of deposit accounts	398,923	2,448	2.43%	389,601	3,213	3.28%
Overnight and short-term borrowings	41,566	19	0.19%	52,493	209	1.58%
	15,326	141	3.63%	10,000	136	5.32%

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form DEF 14A

Wholesale repurchase agreements						
FHLB borrowings	276,722	2,691	3.81%	270,952	2,864	4.20%
Subordinated deferrable interest debentures	13,403	175	5.18%	13,403	234	6.97%
Total interest-bearing liabilities	1,223,867	6,334	2.05%	1,185,860	8,216	2.76%
Noninterest-bearing deposits	197,313			176,491		
Other liabilities	5,866			19,835		
Total liabilities	1,427,046			1,382,186		
Shareholders' equity:	135,820			112,706		
Total liabilities and shareholders' equity	\$ 1,562,866			\$ 1,494,892		
Net interest income		\$ 12,666			\$ 11,921	
Net interest rate spread			3.01%			2.88%
Net interest rate margin			3.38%			3.34%

Table of Contents

Rate/Volume Analysis The following table sets forth certain information regarding changes in the Company's interest income and interest expense for the periods indicated. For each category of interest-earning assets and interest-bearing liabilities, information is provided on changes attributable to (i) changes in rate (changes in rate multiplied by comparative period average balance) and (ii) changes in volume (changes in average balances multiplied by comparative period rate). The net change attributable to the combined impact of rate and volume was allocated proportionally to the individual rate and volume changes.

<i>(In thousands)</i>	Three Months Ended September 30, 2009 vs. 2008		
	Increase/(Decrease) Due to Rate	Volume	Total
Interest income:			
Overnight investments	\$ (4)	\$ (1)	\$ (5)
Available for sale securities	(483)	98	(385)
Stock in the FHLB	(122)	3	(119)
Commercial loans and leases	(1,156)	1,517	361
Residential mortgage loans	(196)	(401)	(597)
Consumer and other loans	(391)	(1)	(392)
 Total interest income	 (2,352)	 1,215	 (1,137)
Interest expense:			
NOW accounts	(22)	2	(20)
Money market accounts	1	122	123
Savings accounts	(749)	(54)	(803)
Certificate of deposit accounts	(840)	75	(765)
Overnight and short-term borrowings	(153)	(36)	(189)
Wholesales repurchase agreements	(52)	56	4
FHLB borrowings	(240)	67	(173)
Subordinated deferrable interest debentures	(59)		(59)
 Total interest expense	 (2,114)	 232	 (1,882)
 Net interest income	 \$ (238)	 \$ 983	 \$ 745

Interest Income Investments Total investment income (consisting of interest on overnight investments, available for sale securities and dividends on FHLB stock) was \$3.9 million for the quarter ended September 30, 2009, compared to \$4.4 million for the 2008 period. The decrease in total investment income was \$509,000, or 11.6%.

With respect to duration and repricing of the Company's available for sale investment portfolio, the majority of the Company's investments are comprised of U.S. Treasury and government-sponsored enterprise (GSE) obligations and private-labeled and GSE mortgage-backed securities with repricing periods or expected durations of less than five years.

Interest Income Loans and Leases - Interest from loans and leases was \$15.1 million for the quarter ended September 30, 2009 and represented a yield on total loans and leases of 5.38%. This compares to \$15.8 million of interest and a yield of 5.91% for the third quarter of 2008. Interest income decreased \$628,000, or 4.0%, with the decrease in yield on loans and leases of 53 bps partially offset by the increase in the average balance of loans and leases of \$57.1 million, or 5.4%.

The average balance of the various components of the loan and lease portfolio changed from the third quarter of 2008 as follows: commercial loans and leases increased \$83.6 million, or 13.2%; consumer and other loans increased \$5.7 million, or 2.8%; and residential mortgage loans decreased \$32.2 million, or 14.7%. Changes in the average yields from the third quarter of 2008 were as follows: commercial loans and leases decreased 54 bps to 5.78%; consumer and other loans decreased 89 bps to 4.46%; and residential mortgage loans decreased 37 bps to 4.92%.

Table of Contents

Interest Expense - Deposits and Borrowings - Interest paid on deposits and borrowings decreased \$1.9 million, or 22.9%, to \$6.3 million for the three months ended September 30, 2009, down from \$8.2 million for the same period during 2008. The overall average cost for interest-bearing liabilities decreased 71 bps to 2.05% for the third quarter of 2009, compared to 2.76% for the third quarter of 2008. The average balance of total interest-bearing liabilities increased \$38.0 million to \$1.22 billion for the three months ended September 30, 2009 compared to the same period in 2008.

The growth in deposit average balances was centered primarily in money market accounts up \$38.1 million, or 706.3%, and CDs up \$9.3 million, or 2.4%. The increase was somewhat offset by a decrease in savings accounts of \$14.2 million, or 3.7%.

Borrowings decreased as compared to the third quarter of 2008, with a decrease in short-term borrowings of \$10.9 million, or 20.8%, offset with an increase in FHLB funding of \$5.8 million, or 2.1%, and repurchase agreements of \$5.3 million, or 53.3%.

Market competition from bank and non-bank financial institutions continues to be strong in the Company's market area. However, lower Federal Funds rates, disciplined deposit pricing and maturation and/or repricing of higher yielding CDs to lower rates have decreased the cost of interest-bearing liabilities in the third quarter of 2009 compared to the same period in 2008.

Overall, the Company's liability costs continue to be dependent upon a number of factors including general economic conditions, national and local interest rates, competition in the local deposit marketplace, interest rate tiers offered and the Company's cash flow needs.

Provision for Loan and Lease Losses

The provision for loan and lease losses was \$1.9 million for the quarter ended September 30, 2009, compared to \$1.5 million for the third quarter of 2008. The Bank made additions to the allowance for loan and lease losses during the third quarter of 2009 in response to increased nonperforming and classified loans, higher charge-offs compared to the prior year third quarter, growth in the commercial loan and lease portfolio and general economic conditions.

Management evaluates several factors including new loan originations, actual and estimated charge-offs, risk characteristics of the loan and lease portfolio and general economic conditions when determining the provision for loan and lease losses. Growth in the loan and lease portfolio necessitates increases in the provision for loan and lease losses. As the loans and leases mature, or if current weak economic conditions continue or worsen, management believes it likely that the level of nonperforming assets would increase, which may in turn lead to increases to the provision for loan and lease losses. Also see discussion under *Allowance for Loan and Lease Losses*.

Noninterest Income

Total noninterest income decreased \$92,000, or 3.9%, to \$2.2 million for the third quarter of 2009, from \$2.3 million for the third quarter of 2008. Impairment on available for sale securities decreased \$149,000, or 68.0%, commissions on nondeposit investment products increased by \$148,000, or 85.1%, and income from bank-owned life insurance increased by \$47,000, or 17.7%. In the third quarter of 2009, the Company experienced lower service charges on deposit accounts of \$73,000, or 5.0%, lower loan related fees of \$61,000, or 44.9%, and lower other miscellaneous income of \$92,000, or 32.4%. Net gains on lease sales and loan commissions were down \$42,000, or 76.4%, as market conditions led to a contraction in the number of buyers for these assets. In addition, the third quarter of 2008 benefited from gains on the sale of available for sale securities of \$168,000, while no securities were sold during the third quarter of 2009.

Noninterest Expense

Noninterest expense for the third quarter of 2009 increased \$508,000, or 5.5%, to \$9.8 million from \$9.3 million in 2008.

Table of Contents

FDIC insurance expense increased \$286,000, or 132.4%, compared to the third quarter a year ago, due to an increase in assessment rates for 2009. During 2008, financial institutions were assessed rates ranging from 5 basis points per \$100 of deposits for institutions in Risk Category I to 43 basis points for institutions assigned to Risk Category IV. In 2009, rates range from 12 to 50 basis points per \$100 of deposits.

Additionally, salaries and employee benefits increased \$157,000, loan workout and other real estate owned expenses increased \$141,000 and other miscellaneous expenses increased \$155,000. The expense increases were partially offset by decreases in professional services of \$100,000, marketing of \$40,000, data processing of \$38,000 and occupancy of \$35,000.

Overall, the increases in FDIC insurance, salaries and employee benefits and loan workout and other real estate owned expense exceeded the cost savings that were realized in the remaining noninterest expense areas. Although the net interest margin for the third quarter of 2009 improved compared to the same period in the prior year, the increases in noninterest expenses combined with the decline in noninterest income caused the Company's efficiency ratio to increase to 65.82% for the third quarter of 2009 compared to the efficiency ratio of 65.27% for the same period in the prior year.

Income Tax Expense

Income tax expense of \$992,000 was recorded for the three months ended September 30, 2009, compared to \$1.1 million for the same period during 2008. This represented total effective tax rates of 31.0% and 32.3%, respectively. A decline in projected pretax income caused the effective tax rate for the third quarter of 2009 to decrease compared to the same quarter of 2008. Tax-favored income from bank-owned life insurance, along with the Company's utilization of a Rhode Island passive investment company, has reduced the effective tax rate from the 40.9% combined statutory federal and state tax rate.

In June 2009, the Bank received a Notice of Assessment from the Massachusetts Department of Revenue (DOR) challenging the 2002 to 2006 state income tax due from BRI Investment Corp., a Rhode Island passive investment company. The DOR seeks to collapse the income from BRI Investment Corp. into the Bank's income and assess state corporate excise tax on the resulting apportioned income. The tax assessment and accrued interest and penalties total approximately \$450,000. The passive investment company is not subject to corporate income tax in the State of Rhode Island. The Bank filed an Application for Abatement in September 2009 contesting the assessment and asserting its position. Management believes it more likely than not that the Bank will prevail in its tax position.

Results of Operations Comparison of the Nine Months Ended September 30, 2009 and 2008**General**

Net income for the first nine months of 2009 decreased \$2.5 million, or 36.1%, to \$4.4 million, or \$0.46 per diluted common share from \$6.9 million, or \$1.49 per diluted common share for the first nine months of 2008.

Net Interest Income

For the nine months ended September 30, 2009, net interest income was \$35.3 million, compared to \$33.7 million for the 2008 period. The net interest margin for the first nine months of 2009 and 2008 was 3.19%. The increase in net interest income of \$1.7 million, or 5.0%, was attributable to savings on interest-bearing liabilities of 75 bps compared to the same period in 2008. Average earning assets were \$70.8 million, or 5.0% higher, and average interest-bearing liabilities were \$35.2 million, or 3.0% higher, than the comparable period a year earlier.

Table of Contents

Average Balances, Yields and Costs - The following table sets forth certain information relating to the Company's average balance sheet and reflects the average yield on assets and average cost of liabilities for the nine month periods indicated. Such yields and costs are derived by dividing income or expense by the average balance of assets or liabilities. Average balances are derived from daily balances and include nonperforming loans and leases. Available for sale securities are stated at amortized cost.

<i>(In thousands)</i>	Nine Months Ended September 30,					
	2009			2008		
	Average Balance	Interest Earned/ Paid	Average Yield	Average Balance	Interest Earned/ Paid	Average Yield
Assets						
Earning assets:						
Overnight investments	\$ 1,607	\$ 10	0.80%	\$ 10,971	\$ 261	3.17%
Available for sale securities	358,019	11,626	4.34%	336,813	12,408	4.92%
Stock in the FHLB	15,790		0.00%	15,671	512	4.36%
Loans and leases receivable:						
Commercial loans and leases	695,368	30,184	5.80%	605,435	29,624	6.53%
Residential mortgage loans	197,588	7,422	5.01%	230,689	9,232	5.34%
Consumer and other loans	211,613	7,110	4.49%	209,608	8,613	5.49%
Total earning assets	1,479,985	56,352	5.08%	1,409,187	60,650	5.74%
Cash and due from banks	19,122			22,395		
Allowance for loan and lease losses	(15,852)			(12,976)		
Premises and equipment	12,528			13,311		
Goodwill, net	12,056			11,969		
Accrued interest receivable	4,286			4,982		
Bank-owned life insurance	29,164			24,536		
Prepaid expenses and other assets	9,787			7,733		
Total assets	\$ 1,551,076			\$ 1,481,137		
Liabilities and Shareholders Equity						
Interest-bearing liabilities:						
Deposits:						
NOW accounts	\$ 64,576	\$ 45	0.09%	\$ 60,970	\$ 138	0.30%
Money market accounts	21,602	192	1.19%	5,632	65	1.53%
Savings accounts	380,308	2,720	0.96%	394,435	5,688	1.93%
Certificate of deposit accounts	414,011	9,069	2.93%	381,522	10,905	3.82%
Overnight and short-term borrowings	46,253	67	0.20%	55,586	853	2.05%
Wholesale repurchase agreements	11,795	408	4.62%	10,000	404	5.32%
FHLB borrowings	258,189	7,966	4.07%	253,420	8,234	4.34%
Subordinated deferrable interest debentures	13,403	564	5.61%	13,403	710	7.07%
Total interest-bearing liabilities	1,210,137	21,031	2.32%	1,174,968	26,997	3.07%

Noninterest-bearing deposits	184,747	175,749	
Other liabilities	11,539	17,013	
Total liabilities	1,406,423	1,367,730	
Shareholders' Equity:	144,653	113,407	
Total liabilities and shareholders' equity	\$ 1,551,076	\$ 1,481,137	
Net interest income	\$ 35,321	\$ 33,653	
Net interest rate spread		2.76%	2.68%
Net interest rate margin		3.19%	3.19%

Table of Contents

Rate/Volume Analysis The following table sets forth certain information regarding changes in the Company's interest income and interest expense for the periods indicated. For each category of interest-earning assets and interest-bearing liabilities, information is provided on changes attributable to (i) changes in rate (changes in rate multiplied by comparative period average balance) and (ii) changes in volume (changes in average balances multiplied by comparative period rate). The net change attributable to the combined impact of rate and volume was allocated proportionally to the individual rate and volume changes.

<i>(In thousands)</i>	Nine Months Ended September 30, 2009 vs. 2008		
	Rate	Volume	Total
Interest income:			
Overnight investments	\$ (117)	\$ (134)	\$ (251)
Available for sale securities	(1,230)	448	(782)
Stock in the FHLB	(516)	4	(512)
Commercial loans and leases	(4,293)	4,853	560
Residential mortgage loans	(554)	(1,256)	(1,810)
Consumer and other loans	(1,342)	(161)	(1,503)
Total interest income	(8,052)	3,754	(4,298)
Interest expense:			
NOW accounts	(100)	7	(93)
Money market accounts	(17)	144	127
Savings accounts	(2,770)	(198)	(2,968)
Certificate of deposit accounts	(2,696)	860	(1,836)
Overnight and short-term borrowings	(662)	(124)	(786)
Wholesale repurchase agreements	(58)	62	4
FHLB borrowings	(440)	172	(268)
Subordinated deferrable interest debentures	(146)		(146)
Total interest expense	(6,889)	923	(5,966)
Net interest income	\$ (1,163)	\$ 2,831	\$ 1,668

Interest Income - Investments - Total investment income (consisting of interest on overnight investments, available for sale securities and dividends on FHLB stock) was \$11.6 million for the nine months ended September 30, 2009, compared to \$13.2 million for the 2008 period. The decrease in total investment income was \$1.5 million, or 11.7%.

With respect to duration and repricing of the Company's available for sale investment portfolio, the majority of the Company's investments are comprised of U.S. Treasury and GSE obligations and private-labeled and GSE mortgage-backed securities with repricing periods or expected durations of less than five years.

Interest Income - Loans and Leases - Interest from loans and leases was \$44.7 million for the nine months ended September 30, 2009, and represented a yield on total loans and leases of 5.41%. This compares to \$47.5 million of interest, and a yield of 6.05%, for the same period a year ago. Interest income decreased \$2.8 million, or 5.8%, with the decrease in yield on loans and leases of 64 bps partially offset by the increase in the average balance of loans and leases of \$58.8 million, or 5.6%.

The average balance of the components of the loan and lease portfolio for the nine months ended September 30, 2009 changed compared to the same period in 2008 as follows: commercial loans and leases increased \$89.9 million, or 14.9%; consumer and other loans increased \$2.0 million, or 1.0%; and residential mortgage loans decreased \$33.1 million, or 14.3%. Changes in the average yields for the nine months ended September 30, 2009 compared to the same period in 2008 were as follows: commercial loans and leases decreased 73 bps to 5.80%; consumer and other loans decreased 100 bps to 4.49%; and residential mortgage loans decreased 33 bps to 5.01%.

Table of Contents

Interest Expense - Deposits and Borrowings - Interest paid on deposits and borrowings decreased \$6.0 million, or 22.1%, to \$21.0 million for the nine months ended September 30, 2009, from \$27.0 million for the same period during 2008. The overall average cost for interest-bearing liabilities decreased 75 bps to 2.32% for the first nine months of 2009, compared to 3.07% for the first nine months of 2008. The average balance of total interest-bearing liabilities increased \$35.2 million to \$1.21 billion for the first nine months of 2009 compared to the same period in 2008. The growth in deposit average balances was centered primarily in CD accounts up \$32.5 million, or 8.5%, and money market accounts up \$16.0 million, or 283.53%. Slightly offsetting the increase in CD accounts were decreases in saving accounts of \$14.1 million, or 3.6%.

The average balance of borrowings decreased for the first nine months of 2009 compared to the prior year, with a decrease in short-term borrowings of \$9.3 million, or 16.8%, slightly offset by an increase in FHLB borrowings of \$4.8 million, or 1.9%.

Market competition from bank and non-bank financial institutions continues to be strong in the Company's market area. However, lower Federal Funds rates, disciplined deposit pricing and maturation and/or repricing of higher yielding CDs to lower rates have decreased the cost of interest-bearing liabilities for the first nine months of 2009 compared to the same period in 2008.

Overall, the Company's liability costs continue to be dependent upon a number of factors including general economic conditions, national and local interest rates, competition in the local deposit marketplace, interest rate tiers offered and the Company's cash flow needs.

Provision for Loan and Lease Losses

For the nine months ended September 30, 2009, the provision for loan and lease losses was \$6.1 million, up from the \$2.8 million recorded during the same period in 2008. The Bank made additions to the allowance for loan and lease losses during the first nine months of 2009 in response to increased nonperforming and classified loans, higher charge-offs compared to the same period in the prior year, growth in the commercial loan portfolio and general economic conditions.

Management evaluates several factors including new loan originations, actual and estimated charge-offs, risk characteristics of the loan and lease portfolio and general economic conditions when determining the provision for loan and lease losses. Growth in the loan and lease portfolio necessitates increases in the provision for loan and lease losses. As the loans and leases mature, or if current weak economic conditions continue or worsen, management believes it likely that the level of nonperforming assets would increase, which may in turn lead to increases to the provision for loan and lease losses. Also see discussion under *Allowance for Loan and Lease Losses*.

Noninterest Income

Total noninterest income decreased \$916,000, or 11.9%, to \$6.8 million for the first nine months of 2009 from \$7.7 million for the same period in 2008. Loan related fees increased by \$260,000, or 58.7%, primarily due to a newly available interest rate swap product, other-than-temporary impairment losses decreased by \$149,000, or 68.0%, and income from bank-owned life insurance increased \$123,000, or 15.7%, compared to the first nine months of 2008. During the first nine months of 2009, the Company recognized lower service charges on deposit accounts of \$379,000, or 8.7%, commissions on nondeposit investment products of \$40,000, or 6.4%, and other miscellaneous income of \$367,000. Net gains on lease sales and loan commissions were down \$313,000, or 83.7%, as market conditions led to a contraction in the number of buyers for these assets. In addition, gains on the sale of available for sale securities decreased \$349,000.

Table of Contents**Noninterest Expense**

Noninterest expense for the first nine months of 2009 increased \$1.2 million, or 4.2%, to \$29.6 million from \$28.4 million in 2008.

FDIC insurance expense increased \$1.6 million, or 332.0%, compared to the first nine months of 2008, due to the special assessment imposed by the FDIC on financial institutions during the second quarter of 2009 and an increase in assessment rates for 2009. On May 22, 2009, the FDIC adopted a final rule imposing a 5 basis point special assessment on all FDIC-insured financial institutions' assets less Tier 1 capital as of June 30, 2009. The rule also permits the FDIC to levy an additional 5 basis points in special assessments after September 30, 2009. In addition to the special assessment, FDIC regular assessments increased for 2009. During 2008, financial institutions were assessed rates ranging from 5 basis points per \$100 of deposits for institutions in Risk Category I to 43 basis points for institutions assigned to Risk Category IV. In 2009, rates range from 12 to 50 basis points per \$100 of deposits.

The increase in FDIC insurance expense was partially offset by decreases in professional services of \$245,000, data processing of \$175,000, marketing of \$126,000, equipment of \$98,000 and other miscellaneous costs of \$61,000.

Overall, with the decrease in noninterest income and the increase in noninterest expense, the Company's efficiency ratio of 70.21% for the first nine months of the year increased from the efficiency ratio of 68.57% for the same period in the prior year.

Income Tax Expense

Income tax expense of \$2.0 million was recorded for the nine months ended September 30, 2009, compared to \$3.3 million for the same period during 2008. This represented total effective tax rates of 31.6% and 32.7%, respectively. Tax-favored income from bank-owned life insurance, along with the Company's utilization of a Rhode Island passive investment company, has reduced the effective tax rate from the 40.9% combined statutory federal and state tax rates.

Liquidity and Capital Resources**Liquidity**

Liquidity is defined as the ability to meet current and future financial obligations of a short-term nature. The Company further defines liquidity as the ability to respond to the needs of depositors and borrowers, as well as to earnings enhancement opportunities, in a changing marketplace.

The primary source of funds for the payment of dividends and expenses by the Company is dividends paid to it by the Bank. Bank regulatory authorities generally restrict the amounts available for payment of dividends if the effect thereof would cause the capital of the Bank to be reduced below applicable capital requirements. These restrictions indirectly affect the Company's ability to pay dividends. The primary sources of liquidity for the Bank consist of deposit inflows, loan repayments, borrowed funds and maturing investment securities and sales of securities from the available for sale portfolio. While management believes that these sources are sufficient to fund the Bank's lending and investment activities, the availability of these funding sources are subject to broad economic conditions and could be restricted in the future. Such restrictions would impact the Company's immediate liquidity and/or additional liquidity. Management is responsible for establishing and monitoring liquidity targets as well as strategies and tactics to meet these targets. In general, the Company seeks to maintain a high degree of flexibility with a liquidity target of 10% to 30% of total assets. At September 30, 2009, overnight investments and available for sale securities amounted to \$366.2 million, or 23.3% of total assets. This compares to \$327.5 million, or 21.4% of total assets at December 31, 2008. The Bank is a member of the FHLB and, as such, has access to both short- and long-term borrowings. The Bank also has access to funding through wholesale repurchase agreements and may utilize additional sources of funding in the future, including borrowings at the Federal Reserve discount window and/or issuance of senior unsecured debt as defined under the FDIC's Temporary Liquidity Guarantee Program. Management believes that the Company has adequate liquidity to meet its commitments.

Table of ContentsCapital Resources

Total shareholders' equity of the Company was \$122.5 million at September 30, 2009 compared to \$149.6 million at December 31, 2008. Net income of \$4.4 million, increased net unrealized holding gains on available for sale securities of \$3.1 million, stock option activity (stock option exercises, share-based compensation and related tax benefits) of \$599,000 and Macrolease contingent share payments of \$78,000 were offset by redemption of preferred stock of \$30.0 million, common stock dividends of \$2.3 million, repurchase of warrant of \$1.4 million, preferred stock dividends of \$892,000, non-credit portion of other-than-temporary impairment of \$406,000 and treasury stock acquisitions of \$254,000.

All FDIC-insured institutions must meet specified minimal capital requirements. These regulations require banks to maintain a minimum leverage capital ratio. In addition, the FDIC has adopted capital guidelines based upon ratios of a bank's capital to total assets adjusted for risk. The risk-based capital guidelines include both a definition of capital and a framework for calculating risk-weighted assets by assigning balance sheet assets and off-balance sheet items to broad risk categories. These regulations require banks to maintain minimum capital levels for capital adequacy purposes and higher capital levels to be considered well-capitalized.

The Federal Reserve Board (FRB) has also issued capital guidelines for bank holding companies. These guidelines require the Company to maintain minimum capital levels for capital adequacy purposes. In general, the FRB has adopted substantially identical capital adequacy guidelines as the FDIC. Such standards are applicable to bank holding companies and their bank subsidiaries on a consolidated basis.

As of September 30, 2009, the Company and the Bank met all applicable minimum capital requirements and were considered well-capitalized by both the FRB and the FDIC.

The Company's and the Bank's actual and required capital amounts and ratios are as follows:

	Actual		Minimum Required For Capital Adequacy Purposes		Minimum Required To Be Considered Well-Capitalized	
	Amount	Ratio	Amount	Ratio	Amount	Ratio
	<i>(Dollars in thousands)</i>					
At September 30, 2009:						
<u>Bancorp Rhode Island, Inc.</u>						
Tier I capital (to average assets)	\$ 120,467	7.80%	\$ 61,785	4.00%	\$ 77,232	5.00%
Tier I capital (to risk weighted assets)	120,467	10.82%	44,538	4.00%	66,807	6.00%
Total capital (to risk weighted assets)	134,413	12.07%	89,076	8.00%	111,345	10.00%
<u>Bank Rhode Island</u>						
Tier I capital (to average assets)	\$ 118,662	7.64%	\$ 62,111	4.00%	\$ 77,639	5.00%
Tier I capital (to risk weighted assets)	118,662	10.66%	44,509	4.00%	66,763	6.00%
Total capital (to risk weighted assets)	132,608	11.92%	89,017	8.00%	111,271	10.00%
At December 31, 2008:						
<u>Bancorp Rhode Island, Inc.</u>						
	\$ 150,169	10.04%	\$ 59,837	4.00%	\$ 74,796	5.00%

Tier I capital (to average assets)						
Tier I capital (to risk weighted assets)	150,169	14.23%	42,202	4.00%	63,302	6.00%
Total capital (to risk weighted assets)	163,368	15.48%	84,403	8.00%	105,504	10.00%

Bank Rhode Island

Tier I capital (to average assets)	\$ 118,197	7.92%	\$ 59,669	4.00%	\$ 74,586	5.00%
Tier I capital (to risk weighted assets)	118,197	11.21%	42,180	4.00%	63,269	6.00%
Total capital (to risk weighted assets)	131,396	12.46%	84,359	8.00%	105,449	10.00%

Table of Contents

On August 5, 2009, the Company repurchased the U.S. Treasury Department's \$30.0 million preferred stock investment and exited the Treasury's Capital Purchase Program (CPP). The Company repurchased all 30,000 shares of Fixed Rate Cumulative Perpetual Preferred Stock, Series A, with a liquidation value of \$1,000 per share and paid accrued dividends through the date of repurchase of \$333,333. The repurchase of the preferred stock investment resulted in the recognition of \$1.3 million in prepayment charges on the discount associated with its issuance. As part of the CPP, the Company also issued the Treasury a warrant to purchase 192,967 shares of common stock with an initial exercise price of \$23.32 per share. On September 30, 2009, the Company repurchased the warrant for \$1.4 million.

The following table sets forth information regarding the effect of preferred stock dividend and discount amounts on earnings per share - diluted. Management believes this non-GAAP measure to be useful in comparing the Company's operating results to the prior year.

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2009	2008	2009	2008
Earnings per share - diluted	\$ 0.17	\$ 0.50	\$ 0.46	\$ 1.49
Effect of preferred shares dividend	0.03		0.19	
Effect of preferred shares discount	0.28		0.30	
Non-GAAP earnings per common share - diluted	\$ 0.48	\$ 0.50	\$ 0.95	\$ 1.49

While the Company was not required to raise additional capital in order to repay the CPP funds, the Company's Board of Directors (the Board) believed it was prudent to assure access to capital on reasonable terms should economic conditions deteriorate more than anticipated. Also, a commitment for additional capital would provide the Company with increased flexibility in responding to market developments.

As a result, the Company entered into a Standby Commitment Letter Agreement (the Commitment Agreement) on August 5, 2009 with a trust of which Malcolm G. Chace, the Company's Chairman of the Board and owner of more than 10% of the Company's outstanding common stock, is a trustee and beneficiary (the Purchaser). Pursuant to this commitment, the Company will have the right, exercisable at any time through February 5, 2011, to require the Purchaser to purchase up to \$8.0 million of trust preferred securities to be issued by a trust subsidiary of the Company (the Trust Subsidiary). At the time of the purchase of the trust preferred securities by the Purchaser, the Company would purchase all of the common securities of the Trust Subsidiary, in an amount equal to at least 3% of the total capital of the Trust Subsidiary. The Trust Subsidiary would in turn use the proceeds from the sale of the trust preferred and the common securities to acquire floating rate junior subordinated notes of the Company. Under the terms of the Commitment Agreement, the Purchaser deposited and must maintain at least \$9.2 million of cash and/or securities in a control account to secure the Purchaser's obligation to purchase the trust preferred securities at the option of the Company. If and when issued, the trust preferred securities will bear interest at a rate equal to the 3-Month LIBOR plus 7.98%, subject to a maximum annual rate of 14.00%. As consideration for the commitment, the Company paid a \$320,000 commitment fee to the Purchaser, representing 4% of the maximum commitment.

Recent Accounting Pronouncements

See *Note 4 - Recent Accounting Pronouncements* of the consolidated financial statements for details of recently issued accounting pronouncements and their expected impact on the Company's consolidated financial statements.

Table of Contents**ITEM 3. Quantitative and Qualitative Disclosures About Market Risk*****Interest Rate Risk***

The principal market risk facing the Company is interest rate risk. The Company's objective regarding interest rate risk is to manage its assets and funding sources to produce results which are consistent with its liquidity, capital adequacy, growth and profitability goals, while maintaining interest rate risk exposure within established parameters over a range of possible interest rate scenarios.

Interest rate risk management is governed by the Bank's Asset/Liability Committee (ALCO). The ALCO establishes exposure limits that define the Company's tolerance for interest rate risk. The ALCO monitors current exposures versus limits and reports results to the Board of Directors. The policy limits and guidelines serve as benchmarks for measuring interest rate risk and for providing a framework for evaluation and interest rate risk management decision making. The primary tools for managing interest rate risk currently are the securities portfolio, purchased mortgages, wholesale repurchase agreements and borrowings from the FHLB.

The Company's interest rate risk position is measured using both income simulation and interest rate sensitivity gap analysis. Income simulation is the primary tool for measuring the interest rate risk inherent in the Company's balance sheet at a given point in time by showing the effect on net interest income, over a 12-month period, of 200 bps interest rate ramps. These simulations take into account repricing, maturity and prepayment characteristics of individual products. The ALCO reviews simulation results to determine whether the exposure resulting from changes in market interest rates remains within established tolerance levels over a 12-month horizon, and develops appropriate strategies to manage this exposure. The Company's guidelines for interest rate risk specify that if interest rates were to shift up or down 200 bps (to not less than a rate of 0.00%) over a 12-month time period, estimated net interest income should decline by no more than 10.0%. As of September 30, 2009, net interest income simulation indicated that the Company's exposure to changing interest rates was within this tolerance. The ALCO reviews the methodology utilized for calculating interest rate risk exposure and may periodically adopt modifications to this methodology.

The following table presents the estimated impact of interest rate ramps on the Company's estimated net interest income over a 12-month period beginning October 1, 2009:

	Estimated Exposure to Net Interest Income	
	Dollar Change	Percent Change
	<i>(Dollars in thousands)</i>	
Initial Twelve Month Period:		
Up 200 bps	\$ (315)	0.6%
Down 200 bps	(3,568)	(6.8%)

The Company also uses interest rate sensitivity gap analysis to provide a more general overview of its interest rate risk profile. The interest rate sensitivity gap is defined as the difference between interest-earning assets and interest-bearing liabilities maturing or repricing within a given time period. At September 30, 2009, the Company's one year cumulative gap was a positive \$128.3 million, or 8.2% of total assets.

For additional discussion on interest rate risk see the section titled *Asset and Liability Management* on pages 52 through 54 of the Company's 2008 Annual Report on Form 10-K.

Table of Contents

ITEM 4. Controls and Procedures

As required by Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the Exchange Act), the Company carried out an evaluation of the effectiveness of the design and operation of the Company s disclosure controls and procedures as of the end of the period covered by this report. This evaluation was carried out under the supervision and with the participation of the Company s management, including the Company s Chief Executive Officer and the Company s Chief Financial Officer. Based upon that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that the Company s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms.

There was no significant change in the Company s internal control over financial reporting that occurred during the Company s most recent fiscal quarter that has materially affected, or is reasonably likely to affect, the Company s internal control over financial reporting. The Company continues to enhance its internal controls over financial reporting, primarily by evaluating and enhancing process and control documentation. Management discusses with and discloses these matters to the Audit Committee of the Board of Directors and the Company s auditors.

Table of Contents

PART II. Other Information

Item 1. Legal Proceedings

There are no material pending legal proceedings to which the Company or its subsidiaries are a party, or to which any of their property is subject, other than ordinary routine litigation incidental to the business of banking.

Item 1A. Risk Factors

There have been no material changes from the risk factors as previously disclosed in the Company's 2008 Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

No information to report.

Item 3. Defaults Upon Senior Securities

No defaults upon senior securities have taken place.

Item 4. Submission of Matters to a Vote of the Security Holders

No information to report.

Item 5. Other Information

No information to report.

Table of Contents

Item 6. Exhibits

- 10.6(b) Amendment No. 2 to Amended and Restated Supplemental Executive Retirement Plan
- 12.1 Computation of Ratios of Earnings to Fixed Charges
- 12.2 Computation of Ratios of Earnings to Fixed Charges and Preferred Stock Dividends
- 31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Table of Contents

BANCORP RHODE ISLAND, INC.
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Bancorp Rhode Island, Inc.

November 4, 2009
(Date)

/s/ Merrill W. Sherman

Merrill W. Sherman
President and Chief Executive Officer

November 4, 2009
(Date)

/s/ Linda H. Simmons

Linda H. Simmons
Chief Financial Officer and Treasurer

Table of Contents

EXHIBIT INDEX

Exhibit Number	Description
10.6(b)	Amendment No. 2 to Amended and Restated Supplemental Executive Retirement Plan
12.1	Computation of Ratios of Earnings to Fixed Charges
12.2	Computation of Ratios of Earnings to Fixed Charges and Preferred Stock Dividends
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.3	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002